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ABSTRACT: Dinuclear metal complexes have emerged as a
promising class of anticancer compounds with the ability to
cross-link biomolecular targets. Here, we describe two novel
series of phosphine-linked dinuclear ruthenium(II) p-cymene
and gold(I) complexes, in which the length of the connecting
poly(ethylene glycol) chain has been systematically modiﬁed.
The impact of the multinuclearity, lipophilicity, and linker
length on the antiproliferative activity of the compounds on
tumorigenic (A2780 and A2780cisR) and nontumorigenic
(HEK-293) cell lines was assessed. The dinuclear ruthenium-
(II) complexes were considerably more cytotoxic than their
mononuclear counterparts, and a correlation between the
lipophilicity of the linker and the cytotoxicity was observed,
whereas the cytotoxicity of the gold(I) series is independent of these factors.
■ INTRODUCTION
The clinical success of cisplatin resulted in considerable eﬀorts
being directed toward the development of other platinum-
based therapeutics.1 However, the need to overcome the
adverse side eﬀects and intrinsic or acquired resistance to these
compounds led to the investigation of alternative metals for
their therapeutic potential.2 Ruthenium(III) complexes imida-
zolium [trans-tetrachloro(1H-imidazole)(S-dimethyl sulfoxide)-
ruthenate(III)]3 and indazolium trans-[tetrachlorobis(1H-
indazole)ruthanate(III)] (KP1019)4−6 and its sodium analogue
(NKP1339)7 have completed phase I and I/II clinical trials.
Ruthenium(II) organometallic compounds have also attracted
attention because they exhibit a number of promising
pharmacological properties.8−10 For example, the so-called
RAPTA complexes (Figure 1),11 of the general formula [Ru(η6-
arene)(PTA)X2] (PTA = 1,3,5-triaza-7-phosphaadamantane),
and the RAED complexes, [Ru(η6-arene)(en)Cl]+ (en =
ethylenediamine),12 have been particularly well studied for
their anticancer properties. RAPTA-C13 and RAED-C,14
(where C = p-cymene) along with their derivatives exhibit an
array of promising in vitro and in vivo properties.9,12,13,15−19
Interestingly, crystallographic studies on the nucleosome core
particle have shown that the choice of ligand strongly inﬂuences
the biomolecular target of ruthenium(II) arene complexes with
RAED-C preferentially binding to DNA and RAPTA-C binding
to the histone proteins.20,21 Mononuclear gold(I) phosphine
complexes have been evaluated for anticancer properties and
exhibit promising activity.22−25 Auranoﬁn (1-thio-β-D-glucopyr-
anose-2,3,4,6-tetraacetato-S)(triethylphosphine)gold(I) (Figure
1), which is used clinically for the treatment of rheumatoid
arthritis,25,26 is currently being repositioned as an anticancer
drug.27−32 Similar to RAPTA complexes,33,34 auranoﬁn
preferentially binds to cysteine-rich proteins such as thioredox-
in reductase (TrX).35−37
Multinuclearity, i.e., covalently connecting two or more metal
centers via an appropriate linker, emerged as an approach to
introducing new modes of action to overcome resistance in
chemoresistant cancers.38 The trinuclear platinum compound
[{trans-PtCl(NH3)2}2-μ-(trans-Pt(NH3)2{H2N(CH2)6-
NH2}2]
4+] (BBR3464; Figure 1) can overcome cisplatin
resistance, and it exhibits a proﬁle of antitumor eﬃcacy distinct
from that of cisplatin in a number of preclinical models.39
However, despite successfully passing phase I clinical trials,
BBR3464 failed a phase II evaluation, with only a minor
response observed in small lung cancer and gastric/gastro-
esophageal adenocarcinoma.40,41
A growing number of multinuclear ruthenium(II) and
gold(I) complexes have also been reported.38 Interest in
homobimetallic ruthenium(II) complexes has focused on the
structure−reactivity investigations and the use of bioactive
bridging ligands such as thiosemicarbazones.42,43 The inﬂuence
of the spacer length on in vitro anticancer activity has
previously been explored using bis(pyridinone)alkane linkers
(η6-p-cymene)Ru(O,O-C6H5O2N(CH2)nNC6H5O2-O,O)Ru-
(η6-p-cymene) (RU1, with n = 3, 6, 12; Figure 1), where the
cytotoxicity correlates to the lipophilicity, which increases with
increasing linker length.44 Both proteins and DNA were
identiﬁed as possible targets for the dinuclear ruthenium(II)
complexes, which hydrolyze rapidly to form active diaqua
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species.45 Interestingly, the cytotoxicity of the complex with the
longest bridging ligand was attributed to the ability of the
complex to form both DNA−DNA and DNA−protein cross-
links.46 A RAED-type binuclear complex, [(Ru(η6-biphenyl)-
Cl(en))2(CH2)6]
2+, similarly bearing an alkyl linker, has been
shown to form interstrand DNA cross-links.47 Flexible alkyl
spacers used in acylpyrazolonato-bridged ruthenium(II) com-
plexes led to complexes with a higher cytotoxicity than those of
related compounds with rigid phenyl spacers.48 Attempts were
made to investigate poly(ethylene glycol) (PEG) linkers;
however, the bis(nicotinate)/bis(isonicotinate) ligands were
unstable in solution.49 Homobinuclear ruthenium(II) com-
plexes linked by diﬀerent stereochemically conﬁgured 1,2-
diphenylethylenediamine spacers exhibit open and closed
Figure 1. Selected examples of dinuclear complexes inspired by well-known monometallic drugs.
Scheme 1. Synthesis of the Diphosphine Ligands (1a−7a), Diruthenium(II) p-Cymene Complexes (1b−7b), Digold(I) Chloride
Intermediates (1c−7c), and Digold(I) β-D-Thioglucosetetraacetate Complexes (1d−7d), Where n = 1−6 and 8
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conformations. The dinuclear complexes are considerably more
cytotoxic than the monomers but did not display cancer cell
selectivity.50 Consequently, a strategy was subsequently
developed to generate dinuclear ruthenium(II) complexes
directly in cancer cells.51
Signiﬁcant eﬀorts have also been devoted to the development
of diphosphinegold(I) complexes.52−58 However, little atten-
tion has been paid to the nature of the linker in homobinuclear
gold(I) complexes. A series of [(AuCl)2(Ph2P-(CH2)nPPh2)]
(where n = 1−6) complexes were prepared and evaluated in
vitro against murine B16 melanoma cells (AU1; Figure 1). The
cytotoxicity initially decreases with the linker length, n = 1 (6
μM) and 2 (8 μM), up to n = 3, where a plateau is reached (n =
3−6, IC50 = 2−3 μM).59 Alkyl linkers were also assessed in
phosphine-bridged dinuclear gold(I) alkynyl complexes linked
via (CH2)n (where n = 1 and 4) groups.
60 More recently,
investigations into the lipophilicity have included the exchange
of hydrophobic PPh3 ligands with more lipophilic PEt3 ligands
in dinuclear phosphinegold(I) sulfanylcarboxylate complexes
resulting in lower IC50 values against selected cell lines.
61 Other
investigations include the optimization of TrX inhibition
bridging bis(N-heterocyclic carbene) ligands,62−64 alkylnyl
ligands,60,65−67 and thiocarbonates.68,69
Because the use of alkyl chains produced a general
dependence between the linker length and cytotoxicity,
correlating with increasing lipophilicity, we decided to evaluate
the eﬀect of PEG chains. Herein, we report the synthesis,
structural characterization, and antiproliferative activity of two
series of dinuclear complexes based on ruthenium(II) and
gold(I) systems. The diruthenium(II) and digold(I) centers are
linked via PEG chains of varying length, while the basic
structures of the parent drugs RAPTA-C and auranoﬁn are
maintained. This strategy allows the inﬂuence of the linker
length on the cytotoxicity to be studied and compared to their
monometallic precursors.
■ RESULTS AND DISCUSSION
Two series of homobinuclear ruthenium(II) p-cymene, 1b−7b,
and gold(I), 1d−7d, derivatives were prepared using the routes
shown in Scheme 1. Universal diphosphine ligands 1a−7a were
synthesized via an esteriﬁcation reaction between 4-
(diphenylphosphanyl)benzoic acid and the appropriate ethyl-
ene glycol in the presence of N-ethyl-N′-[3-(dimethylamino)-
propyl]carbodiimide hydrochloride (EDCI), a coupling agent,
and 4-(dimethylamino)pyridine (DMAP), a basic catalyst.
Ligands 1a−7a were isolated by chromatographic puriﬁcation
in moderate yields (36−64%).
The diruthenium(II) p-cymene complexes 1b−7b were
obtained in high yield (96−98%) in a single step from the
reaction of the appropriate ligands 1a−7a with the [Ru(η6-p-
cymene)Cl2]2 dimer, under inert conditions in dry dichloro-
methane (CH2Cl2; Scheme 1). The binuclear gold(I) β-D-
thioglucosetetraacetate complexes 1d−7d were prepared by
following a two-step strategy (Scheme 1). The intermediate
binuclear gold(I) chloride complexes, 1c−7c, were obtained in
good yield (95−98%) from direct reaction of the appropriate
diphosphine ligands 1a−7a with AuICl(tht) (tht = tetrahy-
drothiophene), freshly prepared following an adapted literature
procedure.70,71 The subsequent reaction of 1c−7c with the β-D-
thioglucosetetraacetate ligand under basic conditions (K2CO3)
in acetone or ethanol (EtOH)/water (H2O) aﬀords the desired
gold(I) complexes 1d−7d in good yield (84−96%).71,72
Mononuclear complexes were also prepared to provide a
structure−activity comparison between the binuclear com-
plexes and the parent drugs, RAPTA-C and auranoﬁn. The
mononuclear ruthenium(II) p-cymene (8b and 9b) and gold(I)
(8d and 9d) complexes, containing 4-(diphenylphosphanyl)-
benzoic acid and triphenylphosphine ligands, were prepared
from the direct reaction of phosphines with the [Ru(η6-p-
cymene)Cl2]2 dimer and Au
ICl(tht) precursors, respectively
(Scheme 2).
All compounds were characterized by 1H, 31P, and 13C NMR
spectroscopy, mass spectrometry (MS), and elemental analysis.
In the 31P NMR spectra, the phosphine ligands 1a−7a produce
a singlet between −4.99 and −5.08 ppm. In the binuclear
complexes, the peaks shift to higher frequencies, with singlet
resonances observed at 24.94−25.00 ppm for 1b−7b, 33.01−
33.14 ppm for 1c−7c, and 38.71−38.79 ppm for 1d−7d,
conﬁrming coordination of the phosphorus centers to the metal
ions. The mononuclear complexes also give rise to singlets
observed in the same range as the binuclear species, i.e., at
24.18 ppm for 8b, 25.28 ppm for 9b, 33.19 ppm for 8c, 33.21
ppm for 9c, 38.83 ppm for 8d, and 38.82 ppm for 9d.
The 1H NMR spectra of the ligands 1a−7a and complexes
also show distinct diﬀerences. The multiplet corresponding to
eight protons ortho to the C−P bond on the phenyl rings shifts
from 7.29−7.39 to 7.76−7.83 ppm (ΔδH ≈ 0.4 ppm), with a
larger shift to 7.85−7.98 ppm (ΔδH ≈ 0.6 ppm) observed for
Scheme 2. Synthesis of Mononuclear Ruthenium(II) p-Cymene (8b and 9b) and Gold(I) (8d and 9d) Complexes
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the four ortho protons on the functionalized ring. Similarly, a
shift of ΔδH ≈ 0.2 ppm to higher frequencies is observed, from
7.29−7.39 ppm (1a−7a) to 7.45−7.60 ppm (1c−7c and 1d−
7d), corresponding to the 12 protons ortho to the C−P bond
in the gold(I) complexes. Complex 8b possesses two multiplets
in the aromatic region: 7.77−7.85 ppm, corresponding to the
six phenyl protons ortho to the C−P bond, and 7.46−7.32
ppm, corresponding to the nine meta and para protons. In
contrast, the 1H NMR spectra of complexes 8c and 8d contain
only one aromatic multiplet that corresponds to all 15 protons
of the triphenylphosphine ligand (8c, 7.42−7.58 ppm; 8d,
7.42−7.59 ppm). Complex 9b possesses a multiplet at 7.97−
8.00 ppm corresponding to the four protons of the function-
alized ring, whereas in 9c and 9d, the multiplets corresponding
to the two protons ortho to the C−P bond are observed at
8.05−8.19 ppm in 9c and 7.81−7.90 ppm in 9d.
Coordination of the ligands to the metal ions is denoted by
the peaks corresponding to the carbon atoms directly
connected to the phosphorus center shifting to lower
frequencies (with increased 1JC,P coupling constants) in the
13C NMR spectra. In the diruthenium(II) p-cymene complexes
1b−7b, a shift of ΔδC ≈ 4.9 ppm and coupling of Δ1JC,P ≈ 28
Hz were observed for the two C−P carbon atoms on the
functionalized ring and ΔδC ≈ 3 ppm and Δ1JC,P ≈ 34 Hz for
the peaks corresponding to the four C−P carbon atoms on the
phenyl rings. An analogous eﬀect was observed for the
digold(I) complexes, for 1c−7c, there is a shift of ΔδC ≈ 9.6
ppm and a coupling of Δ1JC,P ≈ 45 Hz, corresponding to the
two C−P carbon atoms on the functionalized ring and a shift of
ΔδC ≈ 8.5 ppm and Δ1JC,P ≈ 52 Hz representing the four C−P
carbon atoms on the phenyl rings. A comparable, but slightly
less pronounced, eﬀect is observed in the 13C NMR spectra of
1d−7d, and in the mononuclear complexes, similar changes are
also observed.
The impact of increasing PEG chain length on the electronic
environment of the metal centers is negligible, with all coupling
constants and 31P peaks remaining consistently similar
throughout the series.
The most abundant peaks observed in the electrospray
ionization MS (ESI-MS) spectra may be assigned to [M + H]+
and [M + Na]+ ions for ligands 1a−9a, [M − Cl]+ ions for 1b−
9b, [M + Na]+ ions for 1c−8c, [M − H]− ions for 9c, [M −
Cl]+ ions for 1d−7d, and [M + H]+ ions for 8d−9d.
The solid-state structures of 9b and 9c were established by
single-crystal X-ray diﬀraction analysis, conﬁrming the expected
molecular structures. Single crystals of 9b were grown via the
slow evaporation of chloroform from a concentrated solution
(Figure 2). 9b contains four independent molecules in each
asymmetric unit (Figure S1) compared to the two found for
RAPTA-C.73 Key bond parameters are compared with those of
RAPTA-C (Table 1) and, overall, the arrangement around the
ruthenium(II) center is remarkably similar to that of 9b,
adopting the familiar half-sandwich three-legged piano-stool
geometry. The mean Ru−η6 distance is longer in 9b (1.706−
1.723 Å) than in RAPTA-C (1.692−1.701 Å), and the same
trend is observed for the Ru−P bond lengths [9b, 2.363(2)−
2.3691(19) Å; RAPTA-C, 2.296(2)−2.298(3) Å]. The average
Ru−Cl bond lengths and Cl−Ru−Cl angles are similar for both
complexes; however, a diﬀerence is observed in the average P−
Ru−Cl angles, with those in 9b (88.78−89.91°) being
consistently larger than those in RAPTA-C (84.04−87.25°).
In the crystal of 9b, intermolecular hydrogen bonds between
the carboxylic acid groups are observed, leading to the
formation of homodimeric assemblies (Figure S2).
The slow diﬀusion of tetrahydrofuran (THF) into a saturated
solution of 9c in CDCl3 aﬀorded crystals suitable for X-ray
diﬀraction analysis (Figure 3). The bond parameters around the
gold(I) center in 9c are presented in Table 2 and compared
with those of auranoﬁn.74 The Au−P bond distance in 9c
[2.233(9) Å] is comparable to the value observed in auranoﬁn
Figure 2. Solid-state structure of one of the four independent
molecules in 9b. Thermal ellipsoids are 50% equiprobability envelopes.
Hydrogen atoms and solvent molecules (CHCl3) are omitted for
clarity.
Table 1. Comparison of Selected Bond Lengths (Å) and
Angles (deg) in RAPTA-C73 and 9b
RAPTA-Ca 9bb





Ru−Clave 2.421, 2.426 2.420, 2.420, 2.425, 2.420
Cl−Ru−Cl 87.25(8),
88.97(9)
89.85(7), 88.52(7), 89.50(7), 87.51(6)
P−Ru−Clave 85.26, 84.04 89.16, 88.78, 89.91, 89.35
aIn the crystal of RAPTA-C, there are two independent molecules in
the asymmetric unit. bIn 9b, there are four independent complexes in
the asymmetric unit.
Figure 3. Solid-state structure of 9c. Thermal ellipsoids are 50%
equiprobability envelopes. Hydrogen atoms are omitted for clarity.
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(2.259 Å). Despite the diﬀerent labile ligands, i.e., thiol versus
chloride, the Au−Cl bond in 9c [2.286(10) Å] is similar in
length to the Au−S bond in auranoﬁn (2.293 Å). However, the
nature of the labile ligand inﬂuences the angle around the
gold(I) center; the P−Au−Cl [178.07(3)°] angle in 9c is larger
than the auranoﬁn P−Au−S angle (173.6°). The crystal
network in 9c reveals dimeric arrangements due to
intermolecular hydrogen-bonding interactions of the carboxylic
acid group (Figure S3).
The lipophilicity has previously been correlated to increasing
cytotoxicity in dinuclear ruthenium(II) complexes (RU1;
Figure 1).45 Consequently, the partition coeﬃcients (log P)
of PEG chains and alkyl chains were calculated.75,76 As
expected, the lipophilicity of the alkanes increases with
increasing chain length (Chart 1), a trend that is transferred
to diruthenium complexes bearing alkyl linkers of the structure
(η6-p-cymene)Ru(O,O-C6H5O2N(CH2)nNC6H5O2-O,O)Ru-
(η6-p-cymene) (n = 3, 6, and 12).45 In contrast, PEG chains
have limited lipophilicity, with the hydrophobicity increasing
with the chain length up to hexakis(ethylene glycol), where a
plateau is reached. According to calculations, octakis(ethylene
glycol) is the most lipophilic with a log P value of −0.63, and
longer PEG chains become increasingly hydrophilic. The
plateau, consisting of PEG chains 6−9, have similar log P
values in the range −0.62 to −0.67. Log Poctanol/H2O values were
determined experimentally for 1b−7b and 1d−7d using the
shake-ﬂask method (Table 1).77 The log P values reside in the
lipophilic range for both series. Digold(I) β-D-thioglucosete-
traacetate complexes 1d−7d are more hydrophilic than their
ruthenium counterparts 1b−7b because of the presence of two
β-D-thioglucosetetraacetate ligands. For the shorter chain
lengths, 1b−4b and 1d−3d, the lipophilicity was shown to
increase with increasing chain length for both series. However,
for complexes bearing longer chain lengths, 5b−7b and 5d−7b,
the log P values remain essentially constant despite increasing
chain length, values of which are 1.4−1.5 and 0.3−0.4,
respectively.
The cytotoxicity of the 1a−7a ligands and ruthenium(II) p-
cymene 1b−9b and gold(I) β-D-thioglucosetetraacetate 1d−9d
complexes was assessed against human ovarian carcinoma cell
lines, A2780 and A2780cisR, with the latter having acquired
resistance to cisplatin and nontumoral human embryonic
kidney (HEK-293) cells using the 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) assay (Table 3).
The cytotoxicities of 4-(diphenylphosphanyl)benzoic acid,
triphenylphosphine, auranoﬁn, cisplatin, and RAPTA-C were
evaluated for comparison purposes. Elemental analysis indicates
that CH2Cl2 and CDCl3 are present in some compounds;
therefore, their cytotoxicities were evaluated at IC50 concen-
tration, and they were found to be inactive.
All compounds were predissolved in dimethyl sulfoxide
(DMSO), and their stability in this solvent was conﬁrmed via
1H and 31P NMR spectroscopy (Figures S4−S7), before being
immediately diluted into the appropriate cell culture medium.
Further stability studies under pseudocell culture conditions of
100 mM NaCl in H2O and 5% DMSO were conducted on 2d,
4d, and 6d complexes over 72 h. The stability was monitored
via ESI-MS(+) (Figures S8−S10), and all complexes showed
good stability under these conditions.
The original RAPTA series possess low cytotoxicities with
IC50 values of >200 μM against a range of cell lines.
11 As
discussed above, the structures of 9b and RAPTA-C are
comparable, and the similarities are reﬂected in their
cytotoxicities, with IC50 values >200 μM determined against
all tested cell lines. However, the mononuclear ruthenium(II)
complex 8b, bearing a hydrophobic triphenylphosphine ligand,
is considerably more cytotoxic than 9b, with an IC50 of 42 ± 1
μM. A similar trend is present with 8d and 9d, with 9d being
ca. 14-fold more cytotoxic than 8d. The free ligands
triphenylphosphine and 4-(diphenylphosphanyl)benzoic acid
also present respective IC50 values of 85 ± 7 and >200 μM
against the A2780 cell line; the diﬀerences may be attributed to
the diﬀerences in the lipophilicity. However, the impact of
global charge may be of inﬂuence.
The diphosphine ligands 1a−7a are inactive at concen-
trations of up to 500 μM on the three cell lines. The dinuclear
complexes 1b−7b and 1d−7d are considerably more cytotoxic
than the mononuclear complexes 9b and 9d against all cell
lines. The complexes containing the mono(ethylene glycol)
linker (1b and 1d) are considerably less cytotoxic than the
complexes with longer linkers (2b−7b and 2d−7d). In
contrast, in a series of diruthenium(II) p-cymene complexes
with bridging bis(nicotinate)/bis(isonicotinate) ligands, only
the complex with the shortest mono(ethylene glycol) linker
possessed moderate activity against a range of cell lines
including the human melanoma (518A2) cell line (IC50 = 53 ±
1 μM).49
The diruthenium(II) p-cymene complexes 2b−7b exhibit
IC50 values in the low micromolar range against the A2780 cell
line. The cytotoxicity toward the cisplatin-resistant cell line
(A2780cisR) remains in the low micromolar range, with up to
2-fold loss in cytotoxicity compared to the A2780 cisplatin-
sensitive cell line for 3b and 5b. No selectivity was observed
toward the cancer cell lines, with the values obtained for the
nontumorigenic HEK-293 cell line being similar in magnitude.
The cytotoxicities of these dinuclear complexes are comparable
to those of previously investigated series including the series of
rigid RAPTA-type dinuclear complexes, linked via the
Table 2. Comparison of Selected Bond Lengths (Å) and
Angles (deg) in Auranoﬁn74 and 9c
auranoﬁn 9c
Au−P 2.259 Au−P 2.233(9)
Au−S 2.293 Au−Cl 2.286(10)
P−Au−S 173.6 P−Au−Cl 178.07(3)
Chart 1. Calculated Partition Coeﬃcients for Alkyl Chains
and PEG Chains as a Function of the Lengtha
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functionalization of the η6-arene, where the most active
complex has an IC50 of 3.7 ± 0.6 μM against the A2780 cell
line.50
The relationship between the linker length and cytotoxicity
on the A2780 cell line shows increasing cytotoxicity with
increasing linker length between 3b and 5b, which correlates
with the increasing lipophilicity of the linkers. However, 2b
with the bis(ethylene glycol) linker is ca. 2-fold more cytotoxic
than 3b. The lipophilicity is essentially constant for compounds
6b and 7b, with the IC50 values being 7.3 ± 0.3 and 11.6 ± 0.9
μM, respectively.
The digold(I) β-D-thioglucosetetraacetate complexes 1d−7d
are highly cytotoxic on all three tested cell lines, with IC50
values in the low micromolar range. Compounds 2d−7d are
highly cytotoxic against A2780 cells (with IC50 values between
0.17 and 0.25 μM), while being signiﬁcantly less active, up to 8-
fold, on the cisplatin-resistant A2780cisR cell line. The IC50
values of 1d−7d on nontumorigenic HEK-293 cells are very
similar to those on A2780cisR cells. Interestingly, no major
diﬀerences are observed between the activities of the digold(I)
complexes 2d−7d and the mononuclear complex 8d,
containing the hydrophobic PPh3 ligand, whereas 9d, with
t h e mo r e hyd roph i l i c pho sph i n e l i g and , i . e . ,
(C6H5)2PC6H4CO2H, is ca. 35-fold less cytotoxic in A2780
cells and ca. 10-fold less cytotoxic in A2780cisR and HEK-293
cells. With the exception of complexes 1d and 9d, the activities
are in the same order as those of auranoﬁn.
Complexes 2d−7d display a narrow range of IC50 values
between 0.17 ± 0.01 and 0.25 ± 0.02 μM and, thus, there is no
discernible correlation with the linker length and associated
lipophilicity. However, the series is signiﬁcantly more cytotoxic
than [(AuCl)2(Ph2P-(CH2)nPPh2)] (where n = 1−6), in which
the most active complexes (n = 3, 5, and 6) have IC50 values of
ca. 2 μM, again murine B16 melanoma cells.59 A trend was
observed in this alkyl-linked series with 3-fold (n = 1) and 4-
fold (n = 2) higher cytotoxicities for the more lipophilic
complexes.59 The series is also signiﬁcantly more cytotoxic than
the phosphine-bridged dinuclear gold(I) alkynyl complexes
bearing alkyl linkers, where no correlation was observed
between the cytotoxicity and linker length.60
■ CONCLUDING REMARKS
The synthesis of two series of homobinuclear RAPTA-like
ruthenium(II) p-cymene complexes 1b−7b and auranoﬁn-like
gold(I) complexes 1d−7d, linked via diphosphine-modiﬁed
PEG chains of varying length, was successfully achieved. The
antiproliferative activity of these compounds was determined
against tumorigenic and nontumorigenic cell lines, and a
distinct increase the cytotoxicity was observed for both series
compared to the mononuclear precursors 9b and 9d. There is a
correlation between the lipophilicity and cytotoxicity of the
diruthenium(II) complexes, which reaches a plateau where the
lipophilicity no longer increases with the length of the PEG
chain, i.e., when n = 6. In contrast, the cytotoxicities of all of the
digold(I) complexes lie within a narrow range and are not
readily correlated to the linker length and associated
lipophilicity.
■ EXPERIMENTAL SECTION
Materials. RuCl3·3H2O was purchased from Precious Metals
Online. All other chemical reagents were purchased from Aldrich, Alfa
Aesar, Acros, and TCI Chemicals and used without further
puriﬁcation. [Ru(η6-p-cymene)Cl2]2
78 and AuCl(tht)70,71 were pre-
pared following literature procedures. CH2Cl2 was dried and degassed
using a PureSolv solvent puriﬁcation system (Innovative Technology
Inc.). Thin-layer chromatography was conducted on Merck 60 F254
Table 3. Calculated Log P Values and in Vitro Antiproliferative Activities of Compounds 1b−9b and 1d−9d against Human
Ovarian Carcinoma (A2780), Human Ovarian Carcinoma Cisplatin Resistant (A2780cisR), and Human Embryonic Kidney 293
(HEK-293) Cell Lines after 72 h of Exposurea
compound log Poctanol/H2O A2780 A2780cisR HEK-293
1b 1.3 ± 0.1 60 ± 2 110 ± 3 66 ± 1
2b 1.3 ± 0.1 10 ± 0.1 11.0 ± 0.7 12.2 ± 0.5
3b 1.6 ± 0.1 19.4 ± 0.3 37.6 ± 1.6 19.6 ± 1.1
4b 1.8 ± 0.3 11.3 ± 0.1 14.6 ± 0.3 14.7 ± 0.9
5b 1.4 ± 0.05 6.4 ± 0.7 12.9 ± 3.7 6.8 ± 0.2
6b 1.4 ± 0.02 7.3 ± 0.3 10.5 ± 0.1 9.1 ± 0.1
7b 1.5 ± 0.02 11.6 ± 0.9 14.1 ± 7.7 14.2 ± 0.3
8b 42 ± 1 35 ± 7 47 ± 1
9b >200 >200 >200
1d 0.4 ± 0.3 1.5 ± 0.1 4.7 ± 0.1 3.3 ± 0.3
2d 0.9 ± 0.1 0.22 ± 0.03 0.67 ± 0.02 1.2 ± 0.1
3d 0.7 ± 0.2 0.19 ± 0.02 0.91 ± 0.01 1.2 ± 0.1
4d 0.6 ± 0.1 0.19 ± 0.02 1.1 ± 0.1 1.2 ± 0.1
5d 0.3 ± 0.2 0.22 ± 0.02 1.4 ± 0.1 1.4 ± 0.1
6d 0.4 ± 0.3 0.17 ± 0.01 1.4 ± 0.04 1.4 ± 0.1
7d 0.3 ± 0.2 0.25 ± 0.02 1.4 ± 0.4 1.4 ± 0.1
8d 0.54 ± 0.07 1 ± 0.1 1.8 ± 0.2
9d 6.9 ± 0.8 12.0 ± 2 11.7 ± 0.4
(C6H5)2PC6H4CO2H >200 >200 >200
P(C6H5)3 85 ± 7
cisplatin 1.3 ± 0.2 11 ± 1 9 ± 1
RAPTA-C >200 >200 >200
auranoﬁn 1.3 ± 0.5 1.5 ± 0.5 1.9 ± 0.6
aValues are given as the mean ± standard deviation (μM).
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TLC silica-gel-coated aluminum sheets and veriﬁed by a UV lamp at
254 nm and KMnO4 staining. Puriﬁcation of the ligands was achieved
via a manual chromatograph using silica gel (Silicycle R12030B) or a
Varian 971-FP ﬂash chromatography system using prepackaged silica
gel columns (Luknova).
Instrumentation and Methods. 1H (400 MHz), 13C (101 MHz),
and 31P (162 MHz) NMR spectra were recorded on a Bruker Avance
II 400 spectrometer at 298 K. Chemical shifts are reported in parts per
million and referenced to deuterated solvent residual peaks (CDCl3:
1H, δ 7.26 ppm; 13C{1H}, δ 77.16 ppm). Coupling constants (J) are
reported in hertz. High-resolution ESI-MS spectra were obtained on a
Thermo-Finnigan LCQ Deca XP Plus quadropole ion-trap instrument
operated in positive-ion or negative-ion mode. Elemental analyses
were carried out by the microanalytical laboratory at EPFL using a
Thermo Scientiﬁc Flash 2000 organic elemental analyzer. UV−vis
spectra were recorded using a SpectroMax M5e multimode microplate
reader (using Sof tMax Pro software, version 6.2.2). The diﬀraction
data of compounds 9b and 9c were measured at low temperature
[100(2) K] using Mo Kα radiation on a Bruker APEX II CCD
diﬀractometer equipped with a Kappa geometry goniometer. The data
sets were reduced by EvalCCD79 and then corrected for absorption.80
The solutions and reﬁnements were performed by SHELX.81,82 The
crystal structures were reﬁned using full-matrix least squares based on
F2, with all non-hydrogen atoms anisotropically deﬁned. Hydrogen
atoms were placed in calculated positions by means of the “riding”
model. The log P values of PEG and alkyl linker compounds were
predicted using the Virtual Computational Chemistry Lab
(VCCLAB).75,76 The experimental log Poctanol/H2O values were
determined using the shake-ﬂask method,77 and the absorbance of
each fraction was recorded using a SpectroMax M5e multimode
microplate reader (using Sof tMax Pro software, version 6.2.2). The
absorbance of the MTT assay 96-well plates was recorded using a
SpectroMax M5e multimode microplate reader (using Sof tMax Pro
software, version 6.2.2).
Synthesis. General Procedure for the Synthesis of the
Diphosphine Ligands 1a−7a. 4-(Diphenylphosphanyl)benzoic acid
(2.2 equiv) and EDCI (2.4 equiv) were dissolved in CH2Cl2 (50 mL)
and stirred under N2 at room temperature (RT) for 15 min. The
appropriate ethylene glycol (1.0 equiv) and DMAP (0.4 equiv) were
added, and the mixture was further stirred for 24 h at RT. The reaction
mixture was washed with H2O (150 mL), and the aqueous phase was
reextracted with CH2Cl2 (2 × 100 mL). The organic phase was
washed with brine (150 mL), dried over anhydrous sodium sulfate,
ﬁltered, and concentrated under reduced pressure. The treated
product was puriﬁed by ﬂash column chromatography using an
adapted elution system of hexanes/ethyl acetate or CH2Cl2/methanol.
The product was recovered as a colorless viscous solid.
Compound 1a. According to the general procedure, 4-
(diphenylphosphanyl)benzoic acid (0.900 g, 2.938 mmol, 2.2 equiv),
mono(ethylene glycol) (0.075 mL, 1.345 mmol, 1 equiv), EDCI
(0.614 g, 3.203 mmol, 2.4 equiv), and DMAP (0.065 g, 0.532 mmol,
0.4 equiv) were stirred for 24 h in CH2Cl2 (50 mL). Yield: 0.216 g,
0.338 mmol, 25%. Elem anal. Calcd for C40H32O4P2: C, 75.23; H, 5.05.
Found: C, 75.55; H, 5.23. 1H NMR (CDCl3): δH 7.97 (4H, m,
4O(CO)(Ar)CCHCHCP, 3JH,H = 8.6 Hz, 4JH,H = 1.4 Hz), 7.29−
7.40 (24H, m, 4O(CO)(Ar)CCHCHCP, 8P(Ar)CCHCHCH,
8P(Ar)CCHCHCH, 4P(Ar)CCHCHCH), 4.64 (4H, s, Ar(C
O)O(CH2)2O).
31P NMR (CDCl3): δP −4.99 (2P). 13C NMR
(CDCl3): δC 166.3 (2C, 2O(CO)(Ar)CCHCHCP), 144.6 (2C, d,
2O(CO)(Ar)CCHCHCP, 1JC,P = 15 Hz), 136.3 (4C, d, 4P(Ar)
CCHCHCH, 1JC,P = 11 Hz), 134.2 (8C, d, 8P(Ar)CCHCHCH,
2JC,P =
20 Hz), 133.3 (4C, d, 4O(CO)(Ar)CCHCHCP, 2JC,P = 19 Hz),
129.8 (2C, 2O(CO)(Ar)CCHCHCP), 129.5 (4C, d, 4O(C
O)(Ar)CCHCHCP, 3JC,P = 6 Hz), 129.3 (4C, 4P(Ar)CCHCHCH),
128.8 (8C, d, 8P(Ar)CCHCHCH, 3JC,P = 7 Hz), 63.0 (2C, 2(Ar)(C
O)O(CH2)2O). ESI-MS(+). Calcd: m/z 639.1854 ([M + H]
+
C40H33O4P2
+). Found: m/z 639.1853.
Compound 2a. According to the general procedure, 4-
(diphenylphosphanyl)benzoic acid (0.900 g, 2.938 mmol, 2.2 equiv),
bis(ethylene glycol) (0.128 mL, 1.349 mmol, 1 equiv), EDCI (0.614 g,
3.203 mmol, 2.4 equiv), and DMAP (0.065 g, 0.532 mmol, 0.4 equiv)
were stirred for 24 h in CH2Cl2 (50 mL). Yield: 0.328 g, 0.480 mmol,
36%. Elem anal. Calcd for C42H36O5P2: C, 73.89; H, 5.32. Found: C,
73.56; H, 5.51. 1H NMR (CDCl3): δH 7.94−7.97 (4H, m, 4O(C
O)(Ar)CCHCHCP, 3JH,H = 8.5 Hz,
4JH,H = 1.5 Hz), 7.29−7.39 (24H,
m, 4O(CO)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)-
CCHCHCH, 4P(Ar)CCHCHCH), 4.46−4.49 (4H, m, 2Ar(C
O)OCH2CH2O), 3.82−3.87 (4H, m, 2Ar(CO)OCH2CH2O). 31P
NMR (CDCl3): δP −5.08 (2P). 13C NMR (CDCl3): δC 166.4 (2C,
2O(CO)(Ar)CCHCHCP), 144.3 (2C, d, 2O(CO)(Ar)-
CCHCHCP, 1JC,P = 14 Hz), 136.3 (4C, d, 4P(Ar)CCHCHCH,
1JC,P
= 11 Hz), 134.1 (8C, d, 8P(Ar)CCHCHCH, 2JC,P = 20 Hz), 133.2
(4C, d, 4O(CO)(Ar)CCHCHCP, 2JC,P = 19 Hz), 130.0 (2C,
2O(CO)(Ar)CCHCHCP), 129.5 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 3JC,P = 6 Hz), 129.3 (4C, 4P(Ar)CCHCHCH), 128.8
(8C, d, 8P(Ar)CCHCHCH, 3JC,P = 7 Hz), 69.3 (2C, 2(Ar)(C
O)OCH2CH2O), 64.2 (2C, 2(Ar)(CO)OCH2CH2O). ESI-MS(+).
Calcd for C42H37O5P2
+: m/z 682.6925 ([M + H]+). Found: m/z
683.2112. Calcd for C42H36NaO5P2
+: 705.1931 ([M + Na]+). Found:
m/z 705.1936.
Compound 3a. According to the general procedure, 4-
(diphenylphosphanyl)benzoic acid (0.900 g, 2.938 mmol, 2.2 equiv),
tris(ethylene glycol) (0.179 mL, 1.340 mmol, 1 equiv), EDCI (0.614 g,
3.203 mmol, 2.4 equiv), and DMAP (0.065 g, 0.532 mmol, 0.4 equiv)
were stirred for 24 h in CH2Cl2 (50 mL). Yield: 0.446 g, 0.614 mmol,
46%. Elem anal. Calcd for C44H40O6P2: C, 72.72; H, 5.55. Found: C,
72.54; H, 5.58. 1H NMR (CDCl3): δH 7.95−7.98 (4H, m, 4O(C
O)(Ar)CCHCHCP, 3JH,H = 8.4 Hz,
4JH,H = 1.4 Hz), 7.29−7.38 (24H,
m, 4O(CO)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)-
CCHCHCH, 4P(Ar)CCHCHCH), 4.43−4.45 (4H, m, 2Ar(C
O)OCH2CH2O), 3.79−3.82 (4H, m, 2Ar(CO)OCH2CH2O), 3.69
(4H, s, 2Ar(CO)O(CH2)2OCH2). 31P NMR (CDCl3): δP −5.07
(2P). 13C NMR (CDCl3): δC 166.4 (2C, 2O(CO)(Ar)-
CCHCHCP), 144.3 (2C, d, 2O(CO)(Ar)CCHCHCP, 1JC,P = 14
Hz), 136.3 (4C, d, 4P(Ar)CCHCHCH, 1JC,P = 11 Hz), 134.1 (8C, d,
8P(Ar)CCHCHCH, 2JC,P = 20 Hz), 133.3 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 2JC,P = 19 Hz), 130.1 (2C, 2O(CO)(Ar)CCHCHCP),
129.5 (4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 6 Hz), 129.3 (4C,
4P(Ar)CCHCHCH), 128.8 (8C, d, 8P(Ar)CCHCHCH, 3JC,P = 7 Hz),
70.9 (2C, 2(Ar)(CO)O(CH2)2OCH2), 69.4 (2C, 2(Ar)(C
O)OCH2CH2O), 64.3 (2C, 2(Ar)(CO)OCH2CH2O). ESI-MS(+).
Calcd for C44H41O6P2
+: m/z 727.2378 ([M + Na]+). Found: m/z
727.2383. Calcd for C44H40NaO5P2
+: m/z 749.2198 ([M + H]+).
Found: m/z 749.2202
Compound 4a. According to the general procedure, 4-
(diphenylphosphanyl)benzoic acid (0.900 g, 2.938 mmol, 2.2 equiv),
tetrakis(ethylene glycol) (0.231 mL, 1.338 mmol, 1 equiv), EDCI
(0.615 g, 3.203, 2.4 equiv), and DMAP (0.065 g, 0.532 mmol, 0.4
equiv) were stirred for 24 h in CH2Cl2 (50 mL). Yield: 0.487 g, 0.632
mmol, 47%. Elem anal. Calcd for C46H44O7P2: C, 71.68; H, 5.75.
Found: C, 71.59, H, 5.83. 1H NMR (CDCl3): δH 7.95−8.00 (4H, m,
4O(CO)(Ar)CCHCHCP, 3JH,H = 8.2 Hz, 4JH,H = 1.6 Hz), 7.29−
7.38 (24H, m, 4O(CO)(Ar)CCHCHCP, 8P(Ar)CCHCHCH,
8P(Ar)CCHCHCH, 4P(Ar)CCHCHCH), 4.43−4.46 (4H, m,
2Ar(CO)OCH2CH2O), 3.77−3.80 (4H, m, 2Ar(CO)-
OCH2CH2O), 3.61−3.70 (8H, m, 2Ar(CO)O(CH2)2O(CH2)2).
31P NMR (CDCl3): δP −5.06 (2P). 13C NMR (CDCl3): δC 166.4 (2C,
2O(CO)(Ar)CCHCHCP), 144.3 (2C, d, 2O(CO)(Ar)-
CCHCHCP, 1JC,P = 14 Hz), 136.3 (4C, d, 4P(Ar)CCHCHCH,
1JC,P
= 11 Hz), 134.1 (8C, d, 8P(Ar)CCHCHCH, 2JC,P = 20 Hz), 133.3
(4C, d, 4O(CO)(Ar)CCHCHCP, 2JC,P = 19 Hz), 130.2 (2C,
2O(CO)(Ar)CCHCHCP), 129.5 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 3JC,P = 7 Hz), 129.3 (4C, 4P(Ar)CCHCHCH), 128.8
(8C, d, 8P(Ar)CCHCHCH, 3JC,P = 7 Hz), 70.77, 70.79, 70.83 (4C,
2(Ar)(CO)O(CH2)2OCH2, 2(Ar)(CO)O(CH2)2OCH2CH2),
69.3 (2C, 2(Ar)(CO)OCH2CH2O), 64.3 (2C, 2(Ar)(CO)-
OCH2CH2O). ESI-MS(+). Calcd for C46H45O7P2
+: m/z 771.2641
([M + H]+). Found: m/z 771.2630. Calcd for C46H44NaO7P2
+: m/z
793.2460 ([M + Na]+). Found: m/z 793.2451.
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Compound 5a. According to the general procedure, 4-
(diphenylphosphanyl)benzoic acid (0.800 g, 2.612 mmol, 2.2 equiv),
pentakis(ethylene glycol) (0.251 mL, 1.186 mmol, 1 equiv), EDCI
(0.546 g, 2.848 mmol, 2.4 equiv), and DMAP (0.058 g, 0.475 mmol,
0.4 equiv) were stirred for 24 h in CH2Cl2 (50 mL). Yield: 0.621 g,
0.762 mmol, 64%. Elem anal. Calcd for C48H48O8P2: C, 70.75; H, 5.94.
Found: C, 70.85, H, 6.04. 1H NMR (CDCl3): δH 7.96−7.99 (4H, m,
4O(CO)(Ar)CCHCHCP, 3JH,H = 8.4 Hz, 4JH,H = 1.6 Hz), 7.28−
7.37 (24H, m, 4O(CO)(Ar)CCHCHCP, 8P(Ar)CCHCHCH,
8P(Ar)CCHCHCH, 4P(Ar)CCHCHCH), 4.44−4.46 (4H, m,
2Ar(CO)OCH2CH2O), 3.79−3.81 (4H, m, 2Ar(CO)-
OCH2CH2O), 3.65−3.68 (4H, m, 2Ar(CO)O(CH2)2OCH2CH2),
3.61−3.64 (4H, m, 2Ar(CO)O(CH2)2OCH2CH2), 3.62 (4H, s,
2Ar(CO)O(CH2)2O(CH2)2OCH2), 31P NMR (CDCl3): δP −5.08
(2P). 13C NMR (CDCl3): δC 166.4 (2C, 2O(CO)(Ar)-
CCHCHCP), 144.3 (2C, d, 2O(CO)(Ar)CCHCHCP, 1JC,P = 14
Hz), 136.3 (4C, d, 4P(Ar)CCHCHCH, 1JC,P = 11 Hz), 134.1 (8C, d,
8P(Ar)CCHCHCH, 2JC,P = 20 Hz), 133.2 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 2JC,P = 19 Hz), 130.1 (2C, 2O(CO)(Ar)CCHCHCP),
129.5 (4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 6 Hz), 129.1 (4C,
4P(Ar)CCHCHCH), 128.8 (8C, d, 8P(Ar)CCHCHCH, 3JC,P = 7 Hz),
70.80, 70.76, 70.73 (6C, 2(Ar)(CO)O(CH2)2OCH2, 2(Ar)(C
O)O(CH2)2OCH2CH2, 2(Ar)(CO)O(CH2)2O(CH2)2OCH2), 69.3
(2C, 2(Ar)(CO)OCH2CH2O), 64.3 (2C, 2(Ar)(CO)-
OCH2CH2O). ESI-MS(+). Calcd for C48H49O8P2
+: m/z 815.2897
([M + H]+). Found: m/z 815.2905. Calcd for C48H48NaO8P2
+: m/z
837.2722 ([M + Na]+). Found: m/z 837.2723.
Compound 6a. According to the general procedure, 4-
(diphenylphosphanyl)benzoic acid (0.800 g, 2.612 mmol, 2.2 equiv),
hexakis(ethylene glycol) (0.298 mL, 1.190 mmol, 1 equiv), EDCI
(0.546 g, 2.848 mmol, 2.4 equiv), and DMAP (0.058 g, 0.475 mmol,
0.4 equiv) were stirred for 24 h in CH2Cl2 (50 mL). Yield: 0.341 g,
0.397 mmol, 33%. Elem anal. Calcd for C50H52O9P2: C, 69.92; H, 6.10.
Found: C, 70.04; H, 6.13. 1H NMR (CDCl3): δH 7.96−7.99 (4H, m,
4O(CO)(Ar)CCHCHCP, 3JH,H = 8.4 Hz, 4JH,H = 1.2 Hz), 7.28−
7.39 (24H, m, 4O(CO)(Ar)CCHCHCP, 8P(Ar)CCHCHCH,
8P(Ar)CCHCH-CH, 4P(Ar)CCHCHCH), 4.44−4.47 (4H, m,
2Ar(CO)OCH2CH2O), 3.79−3.82 (4H, m, 2Ar(CO)-
OCH2CH2O), 3.66−3.69 (4H, m, 2Ar(CO)O(CH2)2OCH2CH2),
3.61−3.65 (4H, m, 2Ar(CO)O(CH2)2OCH2CH2), 3.58−3.62 (8H,
m, 2Ar(CO)O(CH2)2O(CH2)2O(CH2)2. 31P NMR (CDCl3): δP
5.06 (2P). 13C NMR (CDCl3): δC 166.3 (2C, 2O(CO)(Ar)-
CCHCHCP), 144.1 (2C, d, 2O(CO)(Ar)CCHCHCP, 1JC,P = 14
Hz), 136.1 (4C, d, 4P(Ar)CCHCHCH, 1JC,P = 11 Hz), 133.9 (8C, d,
8P(Ar)CCHCHCH, 2JC,P = 20 Hz), 133.1 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 2JC,P = 19 Hz), 130.0 (2C, 2O(CO)(Ar)CCHCHCP),
129.4 (4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 6 Hz), 129.1 (4C,
4P(Ar)CCHCHCH), 128.7 (8C, d, 8P(Ar)CCHCHCH, 3JC,P = 7 Hz),
70.70, 70.65, 70.63, 70.59 (8C, 2(Ar)(CO)O(CH2)2OCH2, 2(Ar)-
(CO)O(CH2)2OCH2CH2, 2(Ar)(CO)O(CH2)2O(CH2)2OCH2,
2(Ar)(CO)O(CH2)2O(CH2)2OCH2CH2), 69.2 (2C, 2(Ar)(C
O)OCH2CH2O), 64.2 (2C, 2(Ar)(CO)OCH2CH2O). ESI-MS(+).
Calcd for C50H53O9P2
+: m/z 859.3165 ([M + H]+). Found: m/z
859.3168. Calcd for C50H52NaO9P2
+: m/z 881.2984 ([M + Na]+).
Found: m/z 881.2988.
Compound 7a. According to the general procedure, 4-
(diphenylphosphanyl)benzoic acid (0.800 g, 2.612 mmol, 2.2 equiv),
octakis(ethylene glycol) (0.440 g, 1.188 mmol, 1 equiv), EDCI (0.546
g, 2.848 mmol, 2.4 equiv), and DMAP (0.058 g, 0.475 mmol, 0.4
equiv) were stirred for 24 h in CH2Cl2 (50 mL). Yield: 0.499 g, 0.527
mmol, 45%. Elem anal. Calcd for C54H60O11P2: C, 68.49; H, 6.39.
Found: C, 68.16; H, 6.35. 1H NMR (CDCl3): δH 7.96−8.00 (4H, m,
4O(CO)(Ar)CCHCHCP, 3JH,H = 8.4 Hz, 4JH,H = 1.6 Hz), 7.29−
7.37 (24H, m, 4O(CO)(Ar)CCHCHCP, 8P(Ar)CCHCHCH,
8P(Ar)CCHCHCH, 4P(Ar)CCHCHCH), 4.45−4.47 (4H, m,
2Ar(CO)OCH2CH2O), 3.80−3.82 (4H, m, 2Ar(CO)-
OCH2CH2O), 3.67−3.70 (4H, m, 2Ar(CO)O(CH2)2OCH2CH2),
3.63−3.66 (4H, m, 2Ar(CO)O(CH2)2OCH2CH2), 3.60−3.62 (8H,
m, 2Ar(CO)O(CH2)2O(CH2)2O(CH2)2, 3.61 (8H, s, 2Ar(C
O)O(CH2)2O(CH2)2O(CH2)2O(CH2)2.
31P NMR (CDCl3): δP
−5.06 (2P). 13C NMR (CDCl3): δC 166.4 (2C, 2O(CO)(Ar)-
CCHCHCP), 144.4 (2C, d, 2O(CO)(Ar)CCHCHCP, 1JC,P = 15
Hz), 136.5 (4C, d, 4P(Ar)CCHCHCH, 1JC,P = 11 Hz), 134.1 (8C, d,
8P(Ar)CCHCHCH, 2JC,P = 20 Hz), 133.3 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 2JC,P = 19 Hz), 130.1 (2C, 2O(CO)(Ar)CCHCHCP),
129.5 (4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 6 Hz), 129.3 (4C,
4P(Ar)CCHCHCH), 128.8 (8C, d, 8P(Ar)CCHCHCH, 3JC,P = 7 Hz),




(CH2)2O(CH2)2O(CH2)2OCH2CH2), 69.4 (2C, 2(Ar)(CO)-
OCH2CH2O), 64.7 (2C, 2(Ar)(CO)OCH2CH2O). ESI-MS(+).
Calcd for C54H61O11P2
+: m/z 947.3684 ([M + H]+). Found: m/z
947.3671. Calcd for C54H60NaO11P2
+: m/z 969.3509 ([M + Na]+).
Found: m/z 969.3488.
General Procedure for the Synthesis of the Diruthenium
Complexes 1b−7b. [Ru(η6-p-cymene)Cl]2Cl2 (1 equiv) and the
appropriate ligand 1a−7a (1 equiv) in CH2Cl2 (12 mL) were stirred
for 42 h at RT under N2 in the dark. The reaction evolution was
monitored by 1H and 31P NMR (CDCl3). The reaction mixture was
concentrated under reduced pressure and then further dried under
high vacuum to yield the product as a red solid.
Compound 1b. According to the general procedure, [Ru(η6-p-
cymene)Cl]2Cl2 (0.19 g, 0.307 mmol, 1 equiv), 1a (0.20 g, 0.307
mmol, 1 equiv), and CH2Cl2 (12 mL) were stirred for 42 h at RT. The
product was isolated as a dark-red solid. Yield: 0.376 g, 0.301 mmol,
98%. Elem anal. Calcd for C60H60Cl4O4P2Ru2·CH2Cl2: C, 54.84; H,
4.68. Found: C, 54.77; H, 4.93. CH2Cl2 originates from the reaction
solvent. 1H NMR (CDCl3): δH 7.88−7.97 (8H, m, 4O(C
O)(Ar)CCHCHCP, 4O(CO)(Ar)CCHCHCP), 7.77−7.82 (8H,
m, 8P(Ar)CCHCHCH), 7.34−7.44 (12H, m, 8P(Ar)CCHCHCH,
4P(Ar)CCHCHCH), 5.20 (4H, d, 4CH3(Ar)CCHCHC,
3JH,H = 6.1
Hz), 4.98 (4H, d, 4CH3(Ar)CCHCHC,
3JH,H = 6.1 Hz), 4.58 (4H, s,
2A r (CO)OCH 2 CH 2O ) , 2 . 8 3 ( 2H , s e p t , 2 (A r ) -
CCHCHCCH(CH3)2,
3JH,H = 7.2 Hz), 1.84 (6H, s, 2CH3(Ar)-
CCHCHC), 1.09 (12H, d, 2(Ar)CCHCHCCH(CH3)2,
3JH,H = 7.2
Hz). 31P NMR (CDCl3): δP 25.00 (2P).
13C NMR (CDCl3): δC 165.8
(2C, 2O(CO)(Ar)CCHCHCP), 139.7 (2C, d, 2O(CO)(Ar)-
CCHCHCP, 1JC,P = 43 Hz), 134.4 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 2JC,P = 9 Hz), 134.3 (8C, d, 8P(Ar)CCHCHCH,
2JC,P
= 9 Hz), 133.3 (4C, d, 4P(Ar)CCHCHCH, 1JC,P = 45 Hz), 130.9 (2C,
d, 2O(CO)(Ar)CCHCHCP, 4JC,P = 3 Hz), 130.6 (4C, d,
4P(Ar)CCHCHCH, 4JC,P = 2 Hz), 128.8 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 3JC,P = 10 Hz), 128.3 (8C, d, 8P(Ar)CCHCHCH,
3JC,P =
10 Hz), 111.46, 111.43 (2C, 2CH3(Ar)CCHCHC), 96.4 (2C,
2CH3(Ar)CCHCHC), 89.12, 89.09 (4C, 4CH3(Ar)CCHCHC),
87.39, 87.34 (4C, 4CH3(Ar)CCHCHC), 63.0 (2C, 2(Ar)(C
O)OCH2CH2O), 30.4 (2C, 2(Ar)CHCHCCH(CH3)2), 21.9 (4C,
2(Ar)CHCHCCH(CH3)2), 17.9 (2C, 2CH3(Ar)CCHCH). ESI-
MS(+). Calcd for C60H60Cl2O4P2Ru2
+: m/z 1180.1431 ([M −
2Cl]+). Found: m/z 1180.1499. Calcd for C60H60Cl3O4P2Ru2
+: m/z
1215.1119 ([M − Cl]+). Found: m/z 1215.1104. Calcd for
C60H60Cl4NaO4P2Ru2
+: m/z 1273.0706 ([M + Na]+). Found: m/z
1273.0695. UV−vis: λmax = 250 and 370 nm.
Compound 2b. According to the general procedure, [Ru(η6-p-
cymene)Cl]2Cl2 (0.49 g, 0.808 mmol, 1 equiv), 2a (0.55 g, 0.808
mmol, 1 equiv), and CH2Cl2 (12 mL) were stirred for 42 h at RT. The
product was isolated as a dark-red solid. Yield: 1.03 g, 0.791 mmol,
98%. Elem anal. Calcd for C62H64Cl4O5P2Ru2: C, 57.50; H, 4.98.
Found: C, 57.76; H, 5.12. 1H NMR (CDCl3): δH 7.86−7.96 (8H, m,
4O(CO)(Ar)CCHCHCP, 4O(CO)(Ar)CCHCHCP), 7.78−
7.83 (8H, m, 8P(Ar)CCHCHCH), 7.36−7.44 (12H, m, 8P(Ar)-
CCHCHCH, 4P(Ar)CCHCHCH), 5.21 (4H, d, 4CH3(Ar)-
CCHCHC, 3JH,H = 6.2 Hz), 4.98 (4H, d, 4CH3(Ar)CCHCHC,
3JH,H
= 6.2 Hz), 4.45−4.42 (4H, m, 2Ar(CO)OCH2CH2O), 3.83−3.81
(4H, m, 2Ar(CO)OCH2CH2O), 2.85 (2H, sept, 2(Ar)-
CCHCHCCH(CH3)2,
3JH,H = 6.9 Hz), 1.85 (6H, s, 2CH3(Ar)-
CCHCHC), 1.09 (12H, d, 2(Ar)CCHCHCCH(CH3)2,
3JH,H = 6.9
Hz). 31P NMR (CDCl3): δP 24.95 (2P).
13C NMR (CDCl3): δC 166.1
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(2C, 2O(CO)(Ar)CCHCHCP), 139.5 (2C, d, 2O(CO)(Ar)-
CCHCHCP, 1JC,P = 43 Hz), 134.5 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 2JC,P = 9 Hz), 134.4 (8C, d, 8P(Ar)CCHCHCH,
2JC,P
= 9 Hz), 133.4 (4C, d, 4P(Ar)CCHCHCH, 1JC,P = 45 Hz), 131.3 (2C,
d, 2O(CO)(Ar)CCHCHCP, 4JC,P = 2 Hz), 130.7 (4C, d,
4P(Ar)CCHCHCH, 4JC,P = 2 Hz), 128.8 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 3JC,P = 10 Hz), 128.3 (8C, d, 8P(Ar)CCHCHCH,
3JC,P =
10 Hz), 111.59, 111.56 (2C, 2CH3(Ar)CCHCHC), 96.4 (2C,
2CH3(Ar)CCHCHC), 89.15, 89.12 (4C, 4CH3(Ar)CCHCHC),
87.49, 87.43 (4C, 4CH3(Ar)CCHCHC), 69.4 (2C, 2(Ar)(C
O)OCH2CH2O), 64.5 (2C, 2(Ar)(CO)OCH2CH2O), 30.4 (2C,
2(Ar)CHCHCCH(CH3)2), 22.0 (4C, 2(Ar)CHCHCCH(CH3)2),
17 .9 (2C, 2CH3(Ar)CCHCH). ESI-MS(+). Calcd for
C62H64Cl2O5P2Ru2
+: m/z 1224.1693 ([M − 2Cl]+). Found: m/z
1224.1804. Calcd for C62H64Cl3O5P2Ru2
+: m/z 1259.1382 ([M −
Cl]+). Found: m/z 1259.1396. Calcd for C62H64Cl4NaO5P2Ru2
+: m/z
1317.0962 ([M + Na]+). Found: m/z 1317.0995. UV−vis: λmax = 250
and 370 nm.
Compound 3b. According to the general procedure, [Ru(η6-p-
cymene)Cl]2Cl2 (0.15 g, 0.251 mmol, 1 equiv), 3a (0.18 g, 0.251
mmol, 1 equiv), and CH2Cl2 (12 mL) were stirred for 42 h at RT. The
product was isolated as a dark-red solid. Yield: 0.33 g, 0.246 mmol,
98%. Elem anal. Calcd for C64H66Cl4O6P2Ru2·CH2Cl2: C, 54.82; H,
4.95. Found: C, 54.75, H, 4.95. CH2Cl2 originates from the reaction
solvent. 1H NMR (CDCl3): δH 7.86−7.94 (8H, m, 4O(C
O)(Ar)CCHCHCP, 4O(CO)(Ar)CCHCHCP), 7.76−7.82 (8H,
m, 8P(Ar)CCHCHCH), 7.34−7.46 (12H, m, 8P(Ar)CCHCHCH,
4P(Ar)CCHCHCH), 5.19 (4H, d, 4CH3(Ar)CCHCHC,
3JH,H = 6.1
Hz), 4.96 (4H, d, 4CH3(Ar)CCHCHC,
3JH,H = 6.1 Hz), 4.40−4.38
(4H, m, 2Ar(CO)OCH2CH2O), 3.77−3.74 (4H, m, 2Ar(C
O)OCH2CH2O), 3.65 (4H, s, 2Ar(CO)O(CH2)2OCH2), 2.83 (2H,
sept, 2(Ar)CCHCHCCH(CH3)2,
3JH,H = 6.9 Hz), 1.83 (6H, s,
2CH3(Ar)CCHCHC), 1.08 (12H, d, 2(Ar)CCHCHCCH(CH3)2,
3JH,H = 6.9 Hz).
31P NMR (CDCl3): δP 24.94 (2P).
13C NMR
(CDCl3): δC 166.0 (2C, 2O(CO)-(Ar)CCHCHCP), 139.4 (2C, d,
2O(CO)(Ar)CCHCHCP, 1JC,P = 44 Hz), 134.4 (4C, d, 4O(C
O)(Ar)CCHCHCP, 2JC,P = 8 Hz), 134.3 (8C, d, 8P(Ar)CCHCHCH,
2JC,P = 9 Hz), 133.4 (4C, d, 4P(Ar)CCHCHCH,
1JC,P = 45 Hz), 131.4
(2C, m, 2O(CO)(Ar)CCHCHCP), 130.7 (4C, m, 4P(Ar)-
CCHCHCH), 128.8 (4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 10
Hz), 128.3 (8C, d, 8P(Ar)CCHCHCH, 3JC,P = 10 Hz), 111.50, 111.47
(2C, 2CH3(Ar)CCHCHC), 96.4 (2C, 2CH3(Ar)CCHCHC), 89.09,
89.07 (4C, 4CH3(Ar)CCHCHC), 87.43, 87.38 (4C, 4CH3(Ar)-
CCHCHC), 70.8 (2C, 2(Ar)(CO)O(CH2)2OCH2CH2), 69.3
(2C, 2(Ar)(CO)OCH2CH2O), 64.4 (2C, 2(Ar)(CO)-
OCH2CH2O), 30.4 (2C, 2(Ar)CHCHCCH(CH3)2), 22.0 (4C,
2(Ar)CHCHCCH(CH3)2), 17.9 (2C, 2CH3(Ar)CCHCH). ESI-
MS(+). Calcd for C64H68Cl3O6P2Ru2
+: m/z 1303.1644 ([M − Cl]+).
Found: m/z 1303.1660. Calcd for C64H68Cl3NaO6P2Ru2
+: m/z
1361.1224 ([M + Na]+). Found: m/z 1361.1219. UV−vis: λmax =
250 and 370 nm.
Compound 4b. According to the general procedure, [Ru(η6-p-
cymene)Cl]2Cl2 (0.13 g, 0.205 mmol, 1 equiv), 4a (0.16 g, 0.205
mmol, 1 equiv), and CH2Cl2 (12 mL) were stirred for 42 h at RT. The
product was isolated as a red solid. Yield: 0.275 g, 0.199 mmol, 97%.
Elem anal. Calcd for C66H72Cl4O7P2Ru2·
1/2CH2Cl2: C, 56.03; H, 5.06.
Found: C, 55.67; H, 5.16. CH2Cl2 originates from the reaction solvent.
1H NMR (CDCl3): δH 7.85−7.95 (8H, m, 4O(CO)(Ar)-
CCHCHCP, 4O(CO)(Ar)CCHCHCP), 7.76−7.81 (8H, m, 8P-
(Ar)CCHCHCH), 7.34−7.42 (12H, m, 8P(Ar)CCHCHCH, 4P(Ar)-
CCHCHCH), 5.19 (4H, d, 4CH3(Ar)CCHCHC,
3JH,H = 6.2 Hz), 4.96
(4H, d, 4CH3(Ar)CCHCHC,
3JH,H = 6.2 Hz), 4.41−4.38 (4H, m,
2Ar(CO)OCH2CH2O), 3.75−3.73 (4H, m, 2Ar(CO)-
OCH2CH2O), 3.64−3.60 (8H, m, 2Ar(CO)O(CH2)2OCH2CH2,
2Ar(CO)O(CH2)2OCH2CH2), 2.83 (2H, sept, 2(Ar)-
CCHCHCCH(CH3)2,
3JH,H = 6.9 Hz), 1.83 (6H, s, 2CH3(Ar)-
CCHCHC), 1.08 (12H, d, 2(Ar)CCHCHCCH(CH3)2,
3JH,H = 6.9
Hz). 31P NMR (CDCl3): δP 24.96 (2P).
13C NMR (CDCl3): δC 166.1
(2C, 2O(CO)(Ar)CCHCHCP), 139.4 (2C, d, 2O(CO)(Ar)-
CCHCHCP, 1JC,P = 44 Hz), 134.5 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 2JC,P = 8 Hz), 134.4 (8C, d, 8P(Ar)CCHCHCH,
2JC,P
= 9 Hz), 133.4 (4C, d, 4P(Ar)CCHCHCH, 1JC,P = 45 Hz), 131.4 (2C,
d, 2O(CO)(Ar)CCHCHCP, 4JC,P = 2 Hz), 130.7 (4C, d,
4P(Ar)CCHCHCH, 4JC,P = 2 Hz), 128.8 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 3JC,P = 10 Hz), 128.3 (8C, d, 8P(Ar)CCHCHCH,
3JC,P =
10 Hz), 111.54, 111.50 (2C, 2CH3(Ar)CCHCHC), 96.4 (2C,
2CH3(Ar)CCHCHC), 89.11, 89.09 (4C, 4CH3(Ar)CCHCHC),
87.46, 87.40 (4C, 4CH3(Ar)CCHCHC), 70.8, 70.4 (4C, 2(Ar)(C
O)O(CH2)2OCH2, 2(Ar)(CO)O(CH2)2OCH2CH2), 69.2 (2C,
2(Ar)(CO)OCH2CH2O), 64.5 (2C, 2(Ar)(CO)OCH2CH2O),
30.4 (2C, 2(Ar)CHCHCCH(CH3)2), 22.0 (4C, 2(Ar)CHCHCCH-
(CH3)2), 17.9 (2C, 2CH3(Ar)CCHCH). ESI-MS(+). Calcd for
C66H72Cl2O7P2Ru2
2+: 1312.2206 ([M − 2Cl]+). Found: m/z
1312.2328. Calcd for C66H72Cl3O7P2Ru2
+: 1347.1900 ([M − Cl]+).
Found: m/z 1347.1923. Calcd for C66H72Cl4NaO7P2Ru2
+: 1405.1487
([M + Na]+). Found: m/z 1405.1474. UV−vis: λmax = 250 and 370
nm.
Compound 5b. According to the general procedure, [Ru(η6-p-
cymene)Cl]2Cl2 (0.16 g, 0.269 mmol, 1 equiv), 5a (0.22 g, 0.269
mmol, 1 equiv), and CH2Cl2 (12 mL) were stirred for 42 h at RT. The
product was isolated as a red solid. Yield: 0.38 g, 0.263 mmol, 98%.
Elem anal. Calcd for C68H76Cl4O8P2Ru2·
1/2CH2Cl2: C, 55.98; H, 5.28.
Found: C, 55.86; H, 5.34. CH2Cl2 originates from the reaction solvent.
1H NMR (CDCl3): δH 7.88−7.97 (8H, m, 4O(CO)(Ar)-
CCHCHCP, 4O(CO)(Ar)CCHCHCP), 7.77−7.81 (8H, m, 8P-
(Ar)CCHCHCH), 7.35−7.42 (12H, m, 8P(Ar)CCHCHCH, 4P(Ar)-
CCHCHCH), 5.20 (4H, d, 4CH3(Ar)CCHCHC,
3JH,H = 6.1 Hz), 4.96
(4H, d, 4CH3(Ar)CCHCHC,
3JH,H = 6.1 Hz), 4.42−4.39 (4H, m,
2Ar(CO)OCH2CH2O), 3.77−3.74 (4H, m, 2Ar(CO)-
OCH2CH2O), 3.65−3.56 (12H, m, 2Ar(CO)O(CH2)2OCH2CH2,
2Ar(CO)O(CH2)2OCH2CH 2 , 2Ar(CO)O(CH2)2O-
(CH2)2OCH2), 2.83 (2H, sept, 2(Ar)CCHCHCCH(CH3)2,
3JH,H =
6.9 Hz), 1.84 (6H, s, 2CH3(Ar)CCHCHC), 1.09 (12H, d,
2(Ar)CCHCHCCH(CH3)2,
3JH,H = 6.9 Hz).
31P NMR (CDCl3): δP
24.96 (2P). 13C NMR (CDCl3): δC 166.1 (2C, 2O(CO)(Ar)-
CCHCHCP), 139.4 (2C, d, 2O(CO)(Ar)CCHCHCP, 1JC,P = 44
Hz), 134.5 (4C, d, 4O(CO)(Ar)CCHCHCP, 2JC,P = 7 Hz), 134.4
(8C, d, 8P(Ar)CCHCHCH, 2JC,P = 9 Hz), 133.4 (4C, d, 4P(Ar)
CCHCHCH, 1JC,P = 45 Hz), 131.4 (2C, d, 2O(CO)(Ar)
CCHCHCP, 4JC,P = 2 Hz), 130.7 (4C, d, 4P(Ar)CCHCHCH,
4JC,P
= 2 Hz), 128.8 (4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 10 Hz),
128.3 (8C, d, 8P(Ar)CCHCHCH, 3JC,P = 10 Hz), 111.56, 111.53 (2C,
2CH3(Ar)CCHCHC), 96.4 (2C, 2CH3(Ar)CCHCHC), 89.09, 89.11
(4C, 4CH3(Ar)CCHCHC), 87.41, 87.46 (4C, 4CH3(Ar)CCHCHC),
70.8, 70.7 (6C, 2(Ar)(CO)O(CH2)2OCH2, 2(Ar)(CO)O-
(CH2)2OCH2CH2, 2(Ar)(CO)O(CH2)2O(CH2)2OCH2), 69.2
(2C, 2(Ar)(CO)OCH2CH2O), 64.5 (2C, 2(Ar)(CO)-
OCH2CH2O), 30.4 (2C, 2(Ar)CHCHCCH(CH3)2), 22.0 (4C,
2(Ar)CHCHCCH(CH3)2), 17.9 (2C, 2CH3(Ar)CCHCH). ESI-
MS(+). Calcd for C68H76Cl2O8P2Ru2
2+: m/z 1356.2583 ([M −
2Cl]+). Found: m/z 1356.2609. Calcd for C68H76Cl3O8P2Ru2
+: m/z
1391.2168 ([M − Cl]+). Found: m/z 1391.2207. Calcd for
C68H76Cl4NaO8P2Ru2
+: m/z 1449.1749 ([M + Na]+). Found: m/z
1449.1803. UV−vis: λmax = 250 and 370 nm.
Compound 6b. According to the general procedure, [Ru(η6-p-
cymene)Cl]2Cl2 (0.16 g, 0.261 mmol, 1 equiv), 6a (0.22 g, 0.261
mmol, 1 equiv), and CH2Cl2 (12 mL) were stirred for 42 h at RT. The
product was isolated as a red solid. Yield: 0.38 g, 0.256 mmol, 98%.
Elem anal. Calcd for C70H80Cl4O9P2Ru2: C, 57.14; H, 5.48. Found: C,
57.05, H, 5.64. 1H NMR (CDCl3): δH 7.88−7.97 (8H, m, 4O(C
O)(Ar)CCHCHCP, 4O(CO)(Ar)CCHCHCP), 7.78−7.83 (8H, m,
8P(Ar)CCHCHCH), 7.36−7.45 (12H, m, 8P(Ar)CCHCHCH, 4P-
(Ar)CCHCHCH), 5.21 (4H, d, 4CH3(Ar)CCHCHC,
3JH,H = 6.2 Hz),
4.97 (4H, d, 4CH3(Ar)CCHCHC,
3JH,H = 6.2 Hz), 4.44−4.41 (4H, m,
2Ar(CO)OCH2CH2O), 3.79−3.77 (4H, m, 2Ar(CO)-
OCH2CH2O), 3.67−3.61 (16H, m, 2Ar(CO)O(CH2)2OCH2CH2,
2Ar(CO)O(CH2)2OCH2CH 2 , 2Ar(CO)O(CH2)2O-
(CH2)2OCH2), 2Ar(CO)O(CH2)2O(CH2)2OCH2CH2), 2.85
(2H, sept, 2(Ar)CCHCHCCH(CH3)2,
3JH,H = 6.9 Hz), 1.86 (6H, s,
2CH3(Ar)CCHCHC), 1.10 (12H, d, 2(Ar)CCHCHCCH(CH3)2,
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3JH,H = 6.9 Hz).
31P NMR (CDCl3): δP 24.96 (2P).
13C NMR
(CDCl3): δC 166.1 (2C, 2O(CO)(Ar)CCHCHCP), 139.4 (2C, d,
2O(CO)(Ar)CCHCHCP, 1JC,P = 44 Hz), 134.5 (4C, d, 4O(C
O)(Ar)CCHCHCP, 2JC,P = 7 Hz), 134.4 (8C, d, 8P(Ar)CCHCHCH,
2JC,P = 9 Hz), 133.4 (4C, d, 4P(Ar)CCHCHCH,
1JC,P = 45 Hz), 131.4
(2C, d, 2O(CO)(Ar)CCHCHCP, 4JC,P = 2 Hz), 130.7 (4C, d,
4P(Ar)CCHCHCH, 4JC,P = 2 Hz), 128.8 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 3JC,P = 10 Hz), 128.3 (8C, d, 8P(Ar)CCHCHCH,
3JC,P =
10 Hz), 111.61, 111.58 (2C, 2CH3(Ar)CCHCHC), 96.4 (2C,
2CH3(Ar)CCHCHC), 89.13, 89.10 (4C, 4CH3(Ar)CCHCHC),
87.49, 87.44 (4C, 4CH3(Ar)CCHCHC), 70.82, 70.73, 70.67 (8C,
2(Ar)(CO)O(CH2)2OCH2, 2(Ar)(CO)O(CH2)2OCH2CH2, 2-
(Ar)(CO)O(CH2)2O(CH2)2OCH2, 2(Ar)(CO)O(CH2)2O-
(CH2)2OCH2CH2), 69.2 (2C, 2(Ar)(CO)OCH2CH2O), 64.5
(2C, 2(Ar)(CO)OCH2CH2O), 30.4 (2C, 2(Ar)CHCHCCH-
(CH3)2), 22.0 (4C, 2(Ar)CHCHCCH(CH3)2), 17.9 (2C, 2CH3(Ar)-
CCHCH). ESI-MS(+). Calcd for C70H80Cl2O9P2Ru2
2+: m/z
1400.2742 ([M − 2Cl]+). Found: m/z 1400.2695. Calcd for
C70H80Cl3O9P2Ru2
+: m/z 1435.2430 ([M − Cl]+). Found: m/z
1435.2384. Calcd for C70H80Cl4NaO9P2Ru2
+: m/z 1493.2016 ([M +
Na]+). Found: m/z 1493.2328. UV−vis: λmax = 250 and 370 nm.
Compound 7b. According to the general procedure, [Ru(η6-p-
cymene)Cl]2Cl2 (0.18 g, 0.299 mmol, 1 equiv), 7a (0.28 g, 0.299
mmol 1 equiv), and CH2Cl2 (12 mL) were stirred for 42 h at RT. The
product was isolated as a red solid. Yield: 0.45 g, 0.287 mmol, 96%.
Elem anal. Calcd for C74H88Cl4O11P2Ru2: C, 57.00; H, 5.69. Found: C,
56.95; H, 5.90. 1H NMR (CDCl3): δH 7.88−7.98 (8H, m, 4O(C
O)(Ar)CCHCHCP, 4O(CO)(Ar)CCHCHCP), 7.77−7.83 (8H, m,
8P(Ar)CCHCHCH), 7.36−7.45 (12H, m, 8P(Ar)CCHCHCH, 4P-
(Ar)CCHCHCH), 5.21 (4H, d, 4CH3(Ar)CCHCHC,
3JH,H = 6.2 Hz),
4.98 (4H, d, 4CH3(Ar)CCHCHC,
3JH,H = 6.2 Hz), 4.44−4.42 (4H, m,
2Ar(CO)OCH2CH2O), 3.79−3.77 (4H, m, 2Ar(CO)-
OCH2CH2O), 3.70−3.61 (16H, m, 2Ar(CO)O(CH2)2OCH2CH2,
2Ar(CO)O(CH2)2OCH2CH 2 , 2Ar(CO)O(CH2)2O-
(CH2)2OCH2), 2Ar(CO)O(CH2)2O(CH2)2OCH2CH2), 2.85
(2H, sept, 2(Ar)CCHCHCCH(CH3)2,
3JH,H = 6.9 Hz), 1.85 (6H, s,
2CH3(Ar)CCHCHC), 1.10 (12H, d, 2(Ar)CCHCHCCH(CH3)2,
3JH,H = 6.9 Hz).
31P NMR (CDCl3): δP 24.94 (2P).
13C NMR
(CDCl3): δC 166.1 (2C, 2O(CO)(Ar)CCHCHCP), 139.4 (2C, d,
2O(CO)(Ar)CCHCHCP, 1JC,P = 44 Hz), 134.5 (4C, d, 4O(C
O)(Ar)CCHCHCP, 2JC,P = 7 Hz), 134.4 (8C, d, 8P(Ar)CCHCHCH,
2JC,P = 9 Hz), 133.4 (4C, d, 4P(Ar)CCHCHCH,
1JC,P = 45 Hz), 131.4
(2C, d, 2O(CO)(Ar)CCHCHCP, 4JC,P = 2 Hz), 130.7 (4C, d,
4P(Ar)CCHCHCH, 4JC,P = 2 Hz), 128.8 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 3JC,P = 10 Hz), 128.3 (8C, d, 8P(Ar)CCHCHCH,
3JC,P =
10 Hz), 111.59, 111.56 (2C, 2CH3(Ar)CCHCHC), 96.4 (2C,
2CH3(Ar)CCHCHC), 89.12, 89.09 (4C, 4CH3(Ar)CCHCHC),
87.48, 87.42 (4C, 4CH3(Ar)CCHCHC), 70.81, 70.73, 70.67 (8C,
2(Ar)(CO)O(CH2)2OCH2, 2(Ar)(CO)O(CH2)2OCH2CH2, 2-
(Ar)(CO)O(CH2)2O(CH2)2OCH2, 2(Ar)(CO)O(CH2)2O-
(CH2)2OCH2CH2), 69.3 (2C, 2(Ar)(CO)OCH2CH2O), 64.5
(2C, 2(Ar)(CO)OCH2CH2O), 30.4 (2C, 2(Ar)CHCHCCH-
(CH3)2), 22.0 (4C, 2(Ar)CHCHCCH(CH3)2), 17.9 (2C, 2CH3(Ar)-
CCHCH). ESI-MS(+). Calcd for C74H88Cl3O11P2Ru2
+: m/z
1523.2949 ([M − Cl]+). Found: m/z 1523.2914. Calcd for
C74H88Cl4NaO11P2Ru2
+: m/z 1581.2535 ([M + Na]+). Found: m/z
1581.2789. UV−vis: λmax = 250 and 370 nm.
Compound 8b. According to the general procedure, [Ru(η6-p-
cymene)Cl]2Cl2 (0.30 g, 0.490 mmol, 1 equiv), PPh3 (0.26 g, 0.979
mmol, 2 equiv), and CH2Cl2 (12 mL) were stirred for 42 h at RT. The
product was isolated as a dark-red solid. Yield: 0.54 g, 0.950 mmol, 9.
Elem anal. Calcd for C28H29Cl2PRu: C, 59.16; H, 5.14. Found: C,
59.26; H, 4.90. 1H NMR (CDCl3): δH 7.77−7.85 (6H, m,
6P(Ar)CCHCHCH), 7.32−7.46 (9H, m, 6P(Ar)CCHCHCH, 3P-
(Ar)CCHCHCH), 5.19 (2H, d, 2CH3(Ar)CCHCHC,
3JH,H = 6.2 Hz),
4.98 (2H, d, 2CH3(Ar)CCHCHC,
3JH,H = 6.2 Hz), 2.84 (1H, sept,
(Ar)CCHCHCCH(CH3)2,
3JH,H = 7.1 Hz), 1.86 (3H, s, CH3(Ar)-
CCHCHC), 1.09 (6H, d, (Ar)CCHCHCCH(CH3)2,
3JH,H = 7.1 Hz).
31P NMR (CDCl3): δP 24.18 (1P).
13C NMR (CDCl3): δC 134.5 (6C,
d, 6P(Ar)CCHCHCH, 2JC,P = 9 Hz), 133.9 (3C, d, 3P(Ar)
CCHCHCH, 1JC,P = 46 Hz), 130.3 (3C, d, 3P(Ar)CCHCHCH,
4JC,P
= 2 Hz), 128.1 (8C, d, 8P(Ar)CCHCHCH, 3JC,P = 10 Hz), 111.20,
111.17 (1C, CH3(Ar)CCHCHC), 96.1 (1C, 2CH3(Ar)CCHCHC),
89.18, 89.15 (2C, 2CH3(Ar)CCHCHC), 87.28, 87.23 (2C, 2CH3(Ar)-
CCHCHC), 30.3 (1C, (Ar)CHCHCCH(CH3)2), 22.0 (2C, (Ar)-
CHCHCCH(CH3)2), 17.8 (1C, CH3(Ar)CCHCH). ESI-MS(+).
Calcd for C28H29PRu
2+: m/z 498.1050 ([M − 2Cl]+). Found: m/z
498.1009. Calcd for C28H29ClPRu
+: m/z 533.0739 ([M − Cl]+).
Found: m/z 533.0772.
Compound 9b. According to the general procedure, [Ru(η6-p-
cymene)Cl] 2Cl 2 (0 .30 g , 0 .980 mmol , 1 equ iv) , 4 -
(diphenylphosphanyl)benzoic acid (0.30 g, 0.980 mmol, 1 equiv),
and CH2Cl2 (12 mL), were stirred for 42 h at RT. The product was
isolated as a dark-red solid. Yield: 0.59 g, 0.961 mmol, 98%. Elem anal.
Calcd for C29H29Cl2O2PRu.·
1/2CHCl3: C, 52.71; H, 4.42. Found: C,
52.73; H, 4.67. CHCl3 originates from the recrystallization process.
1H
NMR (CDCl3): δH −7.97−8.00 (4H, m, 2O(CO)(Ar)-
CCHCHCP), 7.78−7.84 (4H, m, 4P(Ar)CCHCHCH), 7.36−7.45
(6H, m, 4P(Ar)CCHCHCH, 2P(Ar)CCHCHCH), 5.22 (2H, d,
2CH3(Ar)CCHCHC,
3JH,H = 6.1 Hz), 4.99 (2H, d, 2CH3(Ar)-
CCHCHC, 3 JH ,H = 6 .1 Hz) , 2 .84 (1H, sept , (Ar) -
CCHCHCCH(CH3)2,
3JH,H = 6.9 Hz), 1.85 (3H, s, CH3(Ar)-
CCHCHC), 1.10 (6H, d, (Ar)CCHCHCCH(CH3)2,
3JH,H = 6.9
Hz). 31P NMR (CDCl3): δP 25.27 (1P).
13C NMR (CDCl3): δC 171.1
(1C, O(CO)(Ar)CCHCHCP), 140.4 (1C, d, O(CO)(Ar)-
CCHCHCP, 1JC,P = 43 Hz), 134.5 (2C, d, 2O(CO)(Ar)-
CCHCHCP, 2JC,P = 11 Hz), 134.4 (4C, d, 4P(Ar)CCHCHCH,
2JC,P
= 10 Hz), 133.3 (2C, d, 2P(Ar)CCHCHCH, 1JC,P = 45 Hz), 130.7
(2C, d, 2P(Ar)CCHCHCH, 4JC,P = 1 Hz), 130.5 (1C, d, O(C
O)(Ar)CCHCHCP, 4JC,P = 2 Hz), 129.3 (2C, d, 2O(CO)(Ar)-
CCHCHCP, 3JC,P = 10 Hz), 128.3 (4C, d, 4P(Ar)CCHCHCH,
3JC,P =
10 Hz), 111.57, 111.61 (1C, CH3(Ar)CCHCHC), 96.5 (1C, CH3(Ar)
CCHCHC), 89.06, 89.03 (2C, 2CH3(Ar)CCHCHC), 87.51, 87.46
(2C, 2CH3(Ar)CCHCHC), 30.4 (1C, (Ar)CHCHCCH(CH3)2), 22.0
(2C, (Ar)CHCHCCH(CH3)2), 17.9 (1C, CH3(Ar)CCHCH). ESI-
MS(+). Calcd for C29H29O2PRu
+: m/z 542.0949 ([M − 2Cl]+).
Found: m/z 542.0914. Calcd for C29H29ClO2PRu
+: m/z 577.0637 ([M
− Cl]+). Found: m/z 577.0648. Calcd for C29H29Cl2NaO2PRu+: m/z
635.0223 ([M + Na]+. Found: m/z 635.0228).
General Procedure for the Synthesis of the Digold Intermediates
1c−7c. The appropriate ligand,1a−7a (1 equiv), dissolved in dry
CH2Cl2 (15 mL), was added to a solution of AuCl(tht) (2 equiv) in
dry CH2Cl2 (10 mL) at 0 °C under N2. The reaction mixture was
stirred at RT for 6 h, and the reaction evolution was monitored by 1H
and 31P NMR (CDCl3). The reaction mixture was concentrated under
reduced pressure, and the product was washed with hexane (5 × 25
mL) and resolubilized in CH2Cl2 (50 mL), before being concentrated
and further dried under high vacuum. The product was isolated as a
white solid and stored at −20 °C in the dark.
Compound 1c. According to the general procedure, AuCl(tht)
(0.188 g, 0.588 mmol, 2 equiv), 1a (0.188 g, 0.294 mmol, 1 equiv),
and CH2Cl2 (35 mL) were stirred for 6 h at RT. The product was
isolated as a white solid. Yield: 0.319 g, 0.289 mmol, 98%. Elem anal.
Calcd for C40H32Au2Cl2O4P2: C, 43.54; H, 2.92. Found: C, 43.55; H,
3.02. 1H NMR (CDCl3): δH 8.07−8.12 (4H, m, 4O(CO)(Ar)-
CCHCHCP, 3JH,H = 8.4 Hz,
4JH,H = 2.1 Hz), 7.45−7.60 (24H, m,
4O(CO)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)-
CCHCHCH, 4P(Ar)CCHCHCH), 4.68 (4H, s, Ar(CO)O-
(CH2)2O).
31P NMR (CDCl3): δP 33.14 (2P).
13C NMR (CDCl3):
δC 165.3 (2C, 2O(CO)(Ar)CCHCHCP), 134.9 (2C, d, 2O(C
O)(Ar)CCHCHCP, 1JC,P = 59 Hz), 134.3 (8C, d, 8P(Ar)CCHCHCH,
2JC,P = 14 Hz), 134.1 (4C, d, 4O(CO)(Ar)CCHCHCP, 2JC,P = 14
Hz), 132.9 (2C, d, 2O(CO)(Ar)CCHCHCP, 4JC,P = 3 Hz), 132.5
(4C, d, 4P(Ar)CCHCHCH, 4JC,P = 3 Hz), 130.2 (4C, d, 4O(C
O)(Ar)CCHCHCP, 3JC,P = 12 Hz), 129.6 (8C, d, 8P(Ar)CCHCHCH,
3JC,P = 12 Hz), 127.9 (4C, d, 4P(Ar)CCHCHCH,
1JC,P = 63 Hz), 63.3
(2C, 2(Ar)(CO)O(CH2)2O). ESI-MS(+). Calcd for
C40H32Au2ClO4P2
+: m/z 1067.0795 ([M − Cl]+). Found: m/z
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1067.0825. Calcd for C40H32Au2Cl2NaO4P2
+: m/z 1125.0382 ([M +
Na]+). Found: m/z 1125.0388.
Compound 2c. According to the general procedure, AuCl(tht)
(0.235 g, 0.735 mmol, 2 equiv), 2a (0.250 g, 0.366 mmol,1 equiv), and
CH2Cl2 (35 mL) were stirred for 6 h at RT. The product was isolated
as a white solid. Yield: 0.403 g, 0.351 mmol, 96. Elem anal. Calcd for
C42H36Au2Cl2O5P2: C, 43.96; H, 3.16. Found: C, 43.83; H, 3.23.
1H
NMR (CDCl3): δH 8.06−8.10 (4H, m, 4O(CO)(Ar)CCHCHCP,
3JH,H = 8.2 Hz,
4JH,H = 2 Hz), 7.44−7.60 (24H, m, 4O(C
O)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)CCHCHCH, 4P-
(Ar)CCHCHCH), 4.48−4.50 (4H, m, 2Ar(CO)OCH2CH2O),
3.85−3.87 (4H, m, 2Ar(CO)OCH2CH2O). 31P NMR (CDCl3):
δP 33.02 (2P).
13C NMR (CDCl3): δC 165.4 (2C, 2O(C
O)(Ar)CCHCHCP), 134.6 (2C, d, 2O(CO)(Ar)CCHCHCP,
1JC,P = 62 Hz), 134.3 (8C, d, 8P(Ar)CCHCHCH,
2JC,P = 14 Hz),
134.0 (4C, d, 4O(CO)(Ar)CCHCHCP, 2JC,P = 14 Hz), 133.2 (2C,
d, 2O(CO)(Ar)CCHCHCP, 4JC,P = 2 Hz), 132.5 (4C, d,
4P(Ar)CCHCHCH, 4JC,P = 2 Hz), 130.1 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 3JC,P = 12 Hz), 129.6 (8C, d, 8P(Ar)CCHCHCH,
3JC,P =
12 Hz), 128.0 (4C, d, 4P(Ar)CCHCHCH, 1JC,P = 63 Hz), 69.2 (2C,
2(Ar)(CO)OCH2CH2O), 64.6 (2C, 2(Ar)(CO)OCH2CH2O).
ESI-MS(+). Calcd for C42H36Au2ClO5P2
+: m/z 1111.1058 ([M −
Cl]+). Found: m/z 1111.1104. Calcd for C42H36Au2Cl2NaO5P2
+: m/z
1169.0644 ([M + Na]+).. Found: m/z 1169.0690
Compound 3c. According to the general procedure, AuCl(tht)
(0.221 g, 0.692 mmol, 2 equiv), 3a (0.250 g, 0.344 mmol, 1 equiv),
and CH2Cl2 (35 mL) were stirred 6 h at RT. The product was isolated
as a white solid. Yield: 0.406 g, 0.341 mmol, 98%. Elem anal. Calcd for
C44H40Au2Cl2O6P2: C, 44.35; H, 3.38. Found: C, 44.30; H, 3.51.
1H
NMR (CDCl3): δH 8.07−8.11 (4H, m, 4O(CO)(Ar)CCHCHCP,
3JH,H = 8.4 Hz,
4JH,H = 2.2 Hz), 7.45−7.60 (24H, m, 4O(C
O)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)CCHCHCH, 4P-
(Ar)CCHCHCH), 4.44−4.48 (4H, m, 2Ar(CO)OCH2CH2O),
3.79−3.83 (4H, m, 2Ar(CO)OCH2CH2O), 3.69 (4H, s, 2Ar(C
O)O(CH2)2OCH2).
31P NMR (CDCl3): δP 33.07 (2P).
13C NMR
(CDCl3): δC 165.4 (2C, 2O(CO)(Ar)CCHCHCP), 134.5 (2C, d,
2O(CO)(Ar)CCHCHCP, 1JC,P = 60 Hz), 134.3 (8C, d, 8P(Ar)-
CCHCHCH, 2JC,P = 14 Hz), 134.2 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 2JC,P = 14 Hz), 133.3 (2C, d, 2O(CO)(Ar)
CCHCHCP, 4JC,P = 3 Hz), 132.5 (4C, d, 4P(Ar)CCHCHCH,
4JC,P
= 2 Hz), 130.2 (4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 12 Hz),
129.5 (8C, d, 8P(Ar)CCHCHCH, 3JC,P = 12 Hz), 128.0 (4C, d,
4P(Ar)CCHCHCH, 1JC,P = 63 Hz), 70.8 (2C, 2(Ar)(CO)O-
(CH2)2OCH2), 69.3 (2C, 2(Ar)(CO)OCH2CH2O), 64.7 (2C,
2 (A r ) (CO)OCH2CH 2O ) . E S I -MS ( + ) . C a l c d f o r
C44H40Au2ClO6P2
+: m/z 1155.1320 ([M − Cl]+). Found: m/z
1155.1376. Calcd for C44H40Au2Cl2NaO6P2
+: m/z 1213.0906 ([M +
Na]+). Found: m/z 1213.0951.
Compound 4c. According to the general procedure, AuCl(tht)
(0.208 g, 0.651 mmol, 2 equiv), 4a (0.250 g, 0.324 mmol, 1 equiv),
and CH2Cl2 (35 mL) were stirred 6 h at RT. The product was isolated
as a white solid. Yield: 0.389 g, 0.315 mmol, 97%. Elem anal. Calcd for
C46H44Au2Cl2O7P2: C, 44.71; H, 3.59. Found: C, 44.78; H, 3.57.
1H
NMR (CDCl3): δH 8.08−8.12 (4H, m, 4O(CO)(Ar)CCHCHCP,
3JH,H = 8.4 Hz,
4JH,H = 2 Hz), 7.46−7.60 (24H, m, 4O(C
O)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)CCHCHCH, 4P-
(Ar)CCHCHCH), 4.46−4.49 (4H, m, 2Ar(CO)OCH2CH2O),
3.79−3.82 (4H, m, 2Ar(CO)OCH2CH2O), 3.61−3.72 (8H, m,
2Ar(CO)O(CH2)2O(CH2)2). 31P NMR (CDCl3): δP 33.01 (2P).
13C NMR (CDCl3): δC 165.4 (2C, 2O(CO)(Ar)CCHCHCP),
134.5 (2C, d, 2O(CO)(Ar)CCHCHCP, 1JC,P = 58 Hz), 134.3 (8C,
d, 8P(Ar)CCHCHCH, 2JC,P = 14 Hz), 134.0 (4C, d, 4O(C
O)(Ar)CCHCHCP, 2JC,P = 14 Hz), 133.3 (2C, d, 2O(CO)(Ar)
CCHCHCP, 4JC,P = 2 Hz), 132.4 (4C, d, 4P(Ar)CCHCHCH,
4JC,P = 2
Hz), 130.1 (4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 12 Hz), 129.5
(8C, d, 8P(Ar)CCHCHCH, 3JC,P = 12 Hz), 127.9 (4C, d, 4P(Ar)
CCHCHCH, 1JC,P = 63 Hz), 70.7 (4C, 2(Ar)(CO)O(CH2)2OCH2,
2(Ar)(CO)O(CH2)2OCH2CH2), 69.1 (2C, 2(Ar)(CO)-
OCH2CH2O), 64.7 (2C, 2(Ar)(CO)OCH2CH2O). ESI-MS(+).
Calcd for C46H44Au2ClO7P2
+: m/z 1199.1582 ([M − Cl]+). Found:
m/z 1199.1633. Calcd for C46H44Au2Cl2NaO7P2
+: m/z 1257.1168 ([M
+ Na]+). Found: m/z 1257.1218.
Compound 5c. According to the general procedure, AuCl(tht)
(0.162 g,0.507 mmol, 2 equiv), 5a (0.206 g, 0.253 mmol, 1 equiv), and
CH2Cl2 (35 mL), were stirred for 6 h at RT. The product was isolated
as a white solid. Yield: 0.308 g, 0.241 mmol, 95%. Elem anal. Calcd for
C48H48Au2Cl2O8P2: C, 45.05; H, 3.78. Found: C, 45.05; H, 3.79.
1H
NMR (CDCl3): δH 8.09−8.12 (4H, m, 4O(CO)(Ar)CCHCHCP,
3JH,H = 8.6 Hz,
4JH,H = 2.4 Hz), 7.46−7.60 (24H, m, 4O(C
O)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)CCHCHCH, 4P-
(Ar)CCHCHCH), 4.47−4.49 (4H, m, 2Ar(CO)OCH2CH2O),
3.80−3.82 (4H, m, 2Ar(CO)OCH2CH2O), 3.66−3.68 (4H, m,
2Ar(CO)O(CH2)2OCH2CH2), 3.62−3.64 (4H, m, 2Ar(CO)O-
(CH2)2OCH2CH2), 3.63 (4H, s, 2Ar(CO)O(CH2)2O-
(CH2)2OCH2).
31P NMR (CDCl3): δP 32.99 (2P).
13C NMR
(CDCl3): δC 165.4 (2C, 2O(CO)(Ar)CCHCHCP), 134.3 (2C, d,
2O(CO)(Ar)CCHCHCP, 1JC,P = 57 Hz), 134.3 (8C, d, 8P(Ar)-
CCHCHCH, 2JC,P = 14 Hz), 134.0 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 2JC,P = 14 Hz), 133.3 (2C, d, 2O(CO)(Ar)
CCHCHCP, 4JC,P = 2 Hz), 132.4 (4C, d, 4P(Ar)CCHCHCH,
4JC,P
= 3 Hz), 130.1 (4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 12 Hz),
129.5 (8C, d, 8P(Ar)CCHCHCH, 3JC,P = 12 Hz), 127.9 (4C, d,
4P(Ar)CCHCHCH, 1JC,P = 63 Hz), 70.71, 70.66 (6C, 2(Ar)(C
O)O(CH2)2OCH2, 2(Ar)(CO)O(CH2)2OCH2CH2, 2(Ar)(C
O)O(CH2)2O(CH2)2OCH2), 69.1 (2C, 2(Ar)(CO)OCH2CH2O),
64.7 (2C, 2(Ar)(CO)OCH2CH2O). ESI-MS(+). Calcd for
C48H48Au2ClO8P2
+: m/z 1243.1844 ([M − Cl]+). Found: m/z
1243.1903. Calcd for C48H48Au2Cl2NaO8P2
+: m/z 1301.1430 ([M +
Na]+). Found: m/z 1301.1469.
Compound 6c. According to the general procedure, AuCl(tht)
(0.192 g,0.601 mmol, 2 equiv), 6a (0.257 g, 0.299 mmol, 1 equiv), and
CH2Cl2 (35 mL) were stirred 6 h at RT. The product was isolated as a
white solid. Yield: 0.376 g, 0.284 mmol, 95%. Elem anal. Calcd for
C50H52Au2Cl2O9P2: C, 45.37; H, 3.96. Found: C, 45.44; H, 3.84.
1H
NMR (CDCl3): δH 8.08−8.12 (4H, m, 4O(CO)(Ar)CCHCHCP,
3JH,H = 8.4 Hz,
4JH,H = 2 Hz), 7.45−7.59 (24H, m, 4O(C
O)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)CCHCHCH, 4P-
(Ar)CCHCHCH), 4.46−4.49 (4H, m, 2Ar(CO)OCH2CH2O),
3.79−3.82 (4H, m, 2Ar(CO)OCH2CH2O), 3.65−3.68 (4H, m,
2Ar(CO)O(CH2)2OCH2CH2), 3.60−3.64 (4H, m, 2Ar(CO)O-
(CH2)2OCH2CH2), 3.59−3.62 (8H, m, 2Ar(CO)O(CH2)2O-
(CH2)2O(CH2)2.
31P NMR (CDCl3): δP 33.03 (2P).
13C NMR
(CDCl3): δC 165.4 (2C, 2O(CO)(Ar)CCHCHCP), 134.4 (2C, d,
2O(CO)(Ar)CCHCHCP, 1JC,P = 59 Hz), 134.3 (8C, d, 8P(Ar)-
CCHCHCH, 2JC,P = 14 Hz), 134.1 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 2JC,P = 14 Hz), 133.4 (2C, 2O(CO)(Ar)CCHCHCP),
132.5 (4C, 4P(Ar)CCHCHCH), 130.2 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 3JC,P = 12 Hz), 129.5 (8C, d, 8P(Ar)CCHCHCH,
3JC,P =
12 Hz), 128.0 (4C, d, 4P(Ar)CCHCHCH, 1JC,P = 62 Hz), 70.78,
70.74, 70.68 (8C, 2(Ar)(CO)O(CH2)2OCH2, 2(Ar)(CO)O-
(CH2)2OCH2CH2, 2(Ar)(CO)O(CH2)2O(CH2)2OCH2, 2(Ar)-
(CO)O(CH2)2O(CH2)2OCH2CH2), 69.2 (2C, 2(Ar)(CO)-
OCH2CH2O), 64.8 (2C, 2(Ar)(CO)OCH2CH2O). ESI-MS(+).
Calcd for C50H52Au2ClO9P2
+: m/z 1287.2106 ([M − Cl]+). Found:
m/z 1287.2147.Calcd for C50H52Au2Cl2NaO9P2
+: m/z 1345.1692 ([M
+ Na]+). Found: m/z 1345.1719.
Compound 7c. According to the general procedure, AuCl(tht)
(0.230 g, 0.720 mmol, 2 equiv), 7a (0.340 g, 0.359 mmol, 1 equiv),
and CH2Cl2 (35 mL) were stirred for 6 h at RT. The product was
isolated as a white solid. Yield: 0.485 g, 0.344 mmol, 96%. Elem anal.
Calcd for C54H60Au2Cl2O11P2: C, 45.94; H, 4.28; Found: C, 45.82; H,
4.04. 1H NMR (CDCl3): δH 8.08−8.12 (4H, m, 4O(CO)(Ar)-
CCHCHCP, 3JH,H = 8.2 Hz,
4JH,H = 2 Hz), 7.45−7.59 (24H, m,
4O(CO)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)-
CCHCHCH, 4P(Ar)CCHCHCH), 4.46−4.49 (4H, m, 2Ar(C
O)OCH2CH2O), 3.80−3.82 (4H, m, 2Ar(CO)OCH2CH2O),
3.66−3.69 (4H, m, 2Ar(CO)O(CH2)2OCH2CH2), 3.61−3.64
(4H, m, 2Ar(CO)O(CH2)2OCH2CH2), 3.60−3.62 (8H, m,
2Ar(CO)O(CH2)2O(CH2)2O(CH2)2, 3.61 (8H, s, 2Ar(CO)O-
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(CH2)2O(CH2)2O(CH2)2O(CH2)2.
31P NMR (CDCl3): δP 33.01
(2P). 13C NMR (CDCl3): δC 165.4 (2C, 2O(CO)(Ar)-
CCHCHCP), 134.4 (2C, d, 2O(CO)(Ar)CCHCHCP, 1JC,P = 58
Hz), 134.3 (8C, d, 8P(Ar)CCHCHCH, 2JC,P = 14 Hz), 134.0 (4C, d,
4O(CO)(Ar)CCHCHCP, 2JC,P = 14 Hz), 133.4 (2C, 2O(C
O)(Ar)CCHCHCP, 4JC,P = 2 Hz), 132.4 (4C, 4P(Ar)CCHCHCH,
4JC,P = 2 Hz), 130.2 (4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 12
Hz), 129.5 (8C, d, 8P(Ar)CCHCHCH, 3JC,P = 12 Hz), 128.0 (4C, d,




2(Ar)(CO)O(CH2)2O(CH2)2O(CH2)2OCH2CH2), 69.2 (2C, 2-
(Ar)(CO)OCH2CH2O), 64.8 (2C, 2(Ar)(CO)OCH2CH2O).
ESI-MS(+). Calcd for C54H60Au2ClO11P2
+: m/z 1375.2630 ([M −
Cl]+). Found: m/z 1375.2667. Calcd for C54H60Au2Cl2NaO11P2
+: m/z
1433.2217 ([M + Na]+). Found: m/z 1433.2239.
Compound 8c. According to the general procedure, AuCl(tht)
(0.318 g, 0.995 mmol, 1 equiv), PPh3 (0.260 g, 0.991 mmol, 1 equiv),
and CH2Cl2 (25 mL) were stirred for 4 h at RT. The product was
isolated as a white solid. Yield: 0.471 g, 0.952 mmol, 96%. Elem anal.
Calcd for C18H15AuClP: C, 43.70; H, 3.06. Found: C, 44.02; H, 2.74.
1H NMR (CDCl3): δH 7.42−7.58 (15H, m, 6P(Ar)CCHCHCH,
6P(Ar)CCHCHCH, 3P(Ar)CCHCHCH). 31P NMR (CDCl3): δP
33.19 (1P). 13C NMR (CDCl3): δC 134.2 (6C, d, 6P(Ar)CCHCHCH,
2JC,P = 14 Hz), 132.1 (3C, d, 3P(Ar)CCHCHCH,
4JC,P = 3 Hz), 129.3
(6C, d, 6P(Ar)CCHCHCH, 3JC,P = 12 Hz), 128.8 (3C, d, 3P(Ar)
CCHCHCH, 1JC,P = 62 Hz). ESI-MS(+). Calcd for C18H15AuClNaP
+:
m/z 517.0163 ([M + Na]+). Found: m/z 517.0163.
Compound 9c. According to the general procedure, AuCl(tht)
(0.590 g, 1.846 mmol, 1 equiv), 4-(diphenylphosphanyl)benzoic acid
(0.564 g, 1.841 mmol, 1 equiv), and CH2Cl2 (25 mL) were stirred for
6 h at RT. The product was isolated as a white solid. Yield: 0.962 g,
1.786 mmol, 97%. Elem anal. Calcd for C19H15AuClO2P: C, 42.36; H,
2.81. Found: C, 42.60; H, 2.59. 1H NMR (CDCl3): δH 8.05−8.19 (2H,
m, 2O(CO)(Ar)CCHCHCP, 3JH,H = 8.4 Hz, 4JH,H = 2.1 Hz), 7.47−
7.64 (12H, m, 2O(CO)(Ar)CCHCHCP, 4P(Ar)CCHCHCH,
4P(Ar)CCHCHCH, 2P(Ar)CCHCHCH). 31P NMR (CDCl3): δP
33.21 (1P). 13C NMR (CDCl3): δC 170.5 (1C, O(CO)(Ar)-
CCHCHCP), 135.8 (1C, d, O(CO)(Ar)CCHCHCP, 1JC,P = 58
Hz), 134.4 (4C, d, 2P(Ar)CCHCHCH, 2JC,P = 14 Hz), 134.1 (2C, d,
2O(CO)(Ar)CCHCHCP, 2JC,P = 14 Hz), 132.4 (2C, m, O(C
O)(Ar)CCHCHCP, 2P(Ar)CCHCHCH), 130.6 (2C, d, 2O(C
O)(Ar)CCHCHCP, 3JC,P = 12 Hz), 129.6 (4C, d, 4P(Ar)CCHCHCH,
3JC,P = 12 Hz), 128.1 (2C, d, 2P(Ar)CCHCHCH,
1JC,P = 61 Hz).
Calcd for C19H15AuClO2P: m/z 538.0164. ESI-MS(−). Found: m/z
537.0193 ([M − H]−). Found: m/z 1074.8335 ([2M − H]−).
General Procedure for the Synthesis of the Digold Complexes
1d−7d. The appropriate digold intermediate 1c−7c (1 equiv) was
added to a suspension of β-D-thioglucosetetraacetate (2 equiv) and
K2CO3 (4 equiv) in degassed acetone under N2. The reaction mixture
was stirred under N2 at RT for 48 h in the dark, and the reaction
evolution was veriﬁed by 1H and 31P NMR (CDCl3). The reaction
mixture was concentrated under reduced pressure, the crude was
resuspended in CH2Cl2 and ﬁltered under vacuum. The ﬁltrate was
concentrated under reduced pressure and further dried under high
vacuum. The product was isolated as a white solid and stored at −20
°C in the dark.
Compound 1d. According to the general procedure, β-D-
thioglucosetetraacetate (0.026 g, 0.071 mmol, 2 equiv), K2CO3
(0.050 g, 0.362 mmol, 4 equiv), and 1c (0.100 g, 0.091 mmol, 1
equiv) in acetone (25 mL) were stirred for 48 h at RT in the dark. The
product was isolated as a white solid. Yield: 0.145 g, 0.0824 mmol,
90%. Elem anal. Calcd for C68H70Au2O22P2S2: C, 46.42; H, 4.01.
Found: C, 46.37; H, 3.92. 1H NMR (CDCl3): δH 8.09−8.12 (4H, m,
4O(CO)(Ar)CCHCHCP, 3JH,H = 8.6 Hz, 4JH,H = 2.0 Hz), 7.46−
7.63 (24H, m, 4O(CO)(Ar)CCHCHCP, 8P(Ar)CCHCHCH,
8P(Ar)CCHCHCH, 4P(Ar)CCHCHCH), 5.12−5.17 (4H, m,
SCHCHOAc, SCHCHCHOAc), 5.05 (2H, t, CHCHCH2OAc,
3JH,H
= 9.7 Hz), 5.03 (2H, t, SCHCHOAc, 3JH,H = 9.2 Hz), 4.67 (4H, s,
Ar(CO)O(CH2)2O), 4.20 (2H, dd, CH2OAc, 2JH,H = 12.2 Hz, 3JH,H
= 4.7 Hz), 4.09 (2H, dd, CH2OAc,
2JH,H = 12.2 Hz,
3JH,H = 2.3 Hz),
3.75 (2H, ddd, CHCH2OAc,
3JH,H = 9.7 Hz,
3JH,H = 4.7 Hz,
3JH,H = 2.3
Hz), 2.04 (6H, s, 2CH2O(CO)CH3), 2.00 (6H, s, 2(CO)CH3),
1.96 (6H, s, 2(CO)CH3), 1.89 (6H, s, 2(CO)CH3). 31P NMR
(CDCl3): δP 38.71 (2P).
13C NMR (CDCl3): δC 170.8 (2C, 2(C
O)CH3), 170.3 (2C, 2(CO)CH3), 169.7 (2C, 2(CO)CH3), 169.6
(2C, 2(CO)CH3), 165.4 (2C, 2O(CO)(Ar)CCHCHCP), 135.8
(2C, d, 2O(CO)(Ar)CCHCHCP, 1JC,P = 53 Hz), 134.5 (4C, d,
4P(Ar)CCHCHCH, 2JC,P = 14 Hz), 134.4 (4C, d, 4P(Ar)CCHCHCH,
2JC,P = 14 Hz), 134.2 (4C, d, 4O(CO)(Ar)CCHCHCP, 2JC,P = 14
Hz), 132.5 (2C, d, 2O(CO)(Ar)CCHCHCP, 4JC,P = 2 Hz), 132.1
(4C, m, 4P(Ar)CCHCHCH), 130.1 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 3JC,P = 12 Hz), 129.5 (8C, d, 8P(Ar)CCHCHCH,
3JC,P
= 12 Hz), 128.8 (4C, d, 4P(Ar)CCHCHCH, 1JC,P = 57 Hz), 83.2 (2C,
2CHCH2OAc), 77.8 (2C, SCHCHCHOAc), 75.9 (2C, SCHCHOAc),
74.2 (2C, SCHCHOAc), 69.0 (2C, 2CHCHCH2OAc), 63.2 (2C,
2(Ar)(CO)O(CH2)2O), 62.9 (2C, 2CHCH2(CO)CH3), 21.2
(2C, 2CH2O(CO)CH3), 20.82 (2C, 2(CO)CH3), 20.77 (2C,
2(CO)CH3), 20.72 (2C, 2(CO)CH3). ESI-MS(+). Calcd for
C68H70Au2NaO22P2S2
+: m/z 1781.2499 ([M + Na]+). Found: m/z
1781.2609. Calcd for C54H51Au2O13P2S
+: m/z 1395.1851 ([M −
RS−]+). Found: m/z 1395.2070. UV−vis: λmax = 250 nm.
Compound 2d. According to the general procedure, β-D-
thioglucosetetraacetate (0.107 g, 0.294 mmol, 2 equiv), K2CO3
(0.082 g, 0.593 mmol, 4 equiv), and 2c (0.170 g, 0.148 mmol, 1
equiv) in acetone (25 mL) were stirred for 48 h at RT in the dark. The
product was isolated as a white solid. Yield: 0.223 g, 0.123 mmol, 84%.
Elem anal. Calcd for C70H74Au2O23P2S2: C, 46.62; H, 4.14. Found: C,
46.74; H, 4.10. 1H NMR (CDCl3): δH 8.08−8.12 (4H, m, 4O(C
O)(Ar)CCHCHCP, 3JH,H = 8.5 Hz,
4JH,H = 2 Hz), 7.47−7.65 (24H, m,
4O(CO)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)-
CCHCHCH, 4P(Ar)CCHCHCH), 5.13−5.17 (4H, m, SCHCHOAc,
SCHCHCHOAc), 5.08 (2H, t, CHCHCH2OAc,
3JH,H = 9.2 Hz), 5.04
(2H, t, SCHCHOAc, 3JH,H = 9.2 Hz), 4.48−4.50 (4H, m, 2Ar(C
O)OCH2CH2O), 4.21 (2H, dd, CH2OAc,
2JH,H = 12.2 Hz,
3JH,H = 4.8
Hz), 4.09 (2H, dd, CH2OAc,
2JH,H = 12.2 Hz,
3JH,H = 2.4 Hz), 3.84−
3.87 (4H, m, 2Ar(CO)OCH2CH2O), 3.75 (2H, ddd, CHCH2OAc,
3JH,H = 9.7 Hz,
3JH,H = 4.8 Hz,
3JH,H = 2.4 Hz), 2.04 (6H, s,
2CH2O(CO)CH3), 2.00 (6H, s, 2(CO)CH3), 1.96 (6H, s,
2(CO)CH3), 1.89 (6H, s, 2(CO)CH3). 31P NMR (CDCl3): δP
38.77 (2P). 13C NMR (CDCl3): δC 170.9 (2C, 2(CO)CH3), 170.4
(2C, 2(CO)CH3), 169.8 (2C, 2(CO)CH3), 169.7 (2C, 2(C
O)CH3), 165.6 (2C, 2O(CO)(Ar)CCHCHCP), 135.6 (2C, d,
2O(CO)(Ar)CCHCHCP, 1JC,P = 54 Hz), 134.6 (4C, d, 4P(Ar)-
CCHCHCH, 2JC,P = 14 Hz), 134.5 (4C, d, 4P(Ar)CCHCHCH,
2JC,P =
14 Hz), 134.2 (4C, d, 4O(CO)(Ar)CCHCHCP, 2JC,P = 14 Hz),
132.9 (2C, d, 2O(CO)(Ar)CCHCHCP, 4JC,P = 2 Hz), 132.1 (4C, d,
4P(Ar)CCHCHCH, 4JC,P = 2 Hz), 130.1 (4C, d, 4O(CO)(Ar)-
CCHCHCP, 3JC,P = 12 Hz), 129.5 (8C, d, 8P(Ar)CCHCHCH,
3JC,P =
12 Hz), 129.0 (4C, d, 4P(Ar)CCHCHCH, 1JC,P = 57 Hz), 83.3 (2C,
2CHCH2OAc), 77.8 (2C, SCHCHCHOAc), 75.9 (2C, SCHCHOAc),
74.3 (2C, SCHCHOAc), 69.2 (2C, 2CHCHCH2OAc), 69.1 (2C,
2(Ar)(CO)OCH2CH2O), 64.6 (2C, 2(Ar)(CO)OCH2CH2O),
63.0 (2C, 2CHCH2(CO)CH3), 21.3 (2C, 2CH2O(CO)CH3),
20.86 (2C, 2(CO)CH3), 20.82 (2C, 2(CO)CH3), 20.77 (2C,
2(CO)CH3). ESI-MS(+). Calcd for C70H74Au2NaO23P2S2+: m/z
1825.2761 ([M + Na]+). Found: m/z 1825.2839. Calcd for
C56H55Au2O14P2S
+: m/z 1439.2113 ([M − RS−]+). Found: m/z
1439.2242. UV−vis: λmax = 250 nm.
Compound 3d. According to the general procedure, β-D-
thioglucosetetraacetate (0.107 g, 0.294 mmol, 2 equiv), K2CO3
(0.081 g, 0.586 mmol, 4 equiv), and 3c (0.175 g, 0.147 mmol, 1
equiv) in acetone (25 mL) were stirred for 48 h at RT in the dark. The
product was isolated as a white solid. Yield: 0.258 g, 0.140 mmol, 95%.
Elem anal. Calcd for C72H78Au2O24P2S2: C, 46.81; H, 4.26. Found: C,
47.02; H, 3.98. 1H NMR (CDCl3): δH 8.09−8.12 (4H, m, 4O(C
O)(Ar)CCHCHCP, 3JH,H = 8.5 Hz,
4JH,H = 2.0 Hz), 7.47−7.67 (24H,
m, 4O(CO)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)-
CCHCHCH, 4P(Ar)CCHCHCH), 5.11−5.18 (4H, m, SCHCHOAc,
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SCHCHCHOAc), 5.07 (2H, t, CHCHCH2OAc,
3JH,H = 9.1 Hz), 5.04
(2H, t, SCHCHOAc, 3JH,H = 9.2 Hz), 4.46−4.48 (4H, m, 2Ar(C
O)OCH2CH2O), 4.22 (2H, dd, CH2OAc,
2JH,H = 12.2 Hz,
3JH,H = 4.8
Hz), 4.10 (2H, dd, CH2OAc,
2JH,H = 12.2 Hz,
3JH,H = 2.4 Hz), 3.80−
3.83 (4H, m, 2Ar(CO)OCH2CH2O), 3.76 (2H, ddd, CHCH2OAc,
3JH,H = 9.8 Hz,
3JH,H = 4.8 Hz,
3JH,H = 2.4 Hz), 3.69 (4H, s, 2Ar(C
O)O(CH2)2OCH2), 2.05 (6H, s, 2CH2O(CO)CH3), 2.01 (6H, s,
2(CO)CH3), 1.97 (6H, s, 2(CO)CH3), 1.90 (6H, s, 2(C
O)CH3).
31P NMR (CDCl3): δP 38.79 (2P).
13C NMR (CDCl3): δC
170.9 (2C, 2(CO)CH3), 170.4 (2C, 2(CO)CH3), 169.8 (2C,
2(CO)CH3), 169.7 (2C, 2(CO)CH3), 165.6 (2C, 2O(C
O)(Ar)CCHCHCP), 135.6 (2C, d, 2O(CO)(Ar)CCHCHCP, 1JC,P
= 53 Hz), 134.6 (4C, d, 4P(Ar)CCHCHCH, 2JC,P = 14 Hz), 134.5
(4C, d, 4P(Ar)CCHCHCH, 2JC,P = 14 Hz), 134.2 (4C, d, 4O(C
O)(Ar)CCHCHCP, 2JC,P = 14 Hz), 133.0 (2C, d, 2O(CO)(Ar)
CCHCHCP, 4JC,P = 2 Hz), 132.1 (4C, m, 4P(Ar)CCHCHCH), 130.1
(4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 12 Hz), 129.5 (8C, d,
8P(Ar)CCHCHCH, 3JC,P = 12 Hz), 129.0 (4C, d, 4P(Ar)CCHCHCH,
1JC,P = 57 Hz), 83.3 (2C, 2CHCH2OAc), 77.8 (2C, SCHCHCHOAc),
75.9 (2C, SCHCHOAc), 74.3 (2C, SCHCHOAc), 70.8 (2C,
2(Ar)(CO)O(CH2)2OCH2), 69.3 (2C, 2(Ar)(CO)-
OCH2CH2O), 69.1 (2C, 2CHCHCH2OAc), 64.6 (2C, 2(Ar)(C
O)OCH2CH2O), 63.0 (2C, 2CHCH2(CO)CH3), 21.3 (2C,
2CH2O(CO)CH3), 20.87 (2C, 2(CO)CH3), 20.84 (2C, 2(C
O)CH3), 20.79 (2C, 2(CO)CH3). ESI-MS(+). Calcd for
C72H78Au2NaO24P2S2
+: m/z 1869.3023 ([M + Na]+). Found: m/z
1869.3127. Calcd for C58H59Au2O15P2S
+: m/z 1483.2375 ([M −
RS−]+). Found: m/z 1483.2581. UV−vis: λmax = 250 nm.
Compound 4d. According to the general procedure, β-D-
thioglucosetetraacetate (0.103 g, 0.283 mmol, 2 equiv), K2CO3
(0.079 g, 0.572 mmol, 4 equiv), and 4c (0.175 g, 1 equiv) in acetone
(25 mL) were stirred for 48 h at RT in the dark. The product was
isolated as a white solid. Yield: 0.233 g, 0.123 mmol, 87%. Elem anal.
Calcd for C74H82Au2O25P2S2: C, 46.99; H, 4.37. Found: C, 47.02; H,
4.29. 1H NMR (CDCl3): δH 8.09−8.13 (4H, m, 4O(CO)(Ar)-
CCHCHCP, 3JH,H = 8.5 Hz,
4JH,H = 2.0 Hz), 7.46−7.64 (24H, m,
4O(CO)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)-
CCHCHCH, 4P(Ar)CCHCHCH), 5.13−5.18 (4H, m, SCHCHOAc,
SCHCHCHOAc), 5.09 (2H, t, CHCHCH2OAc,
3JH,H = 9.6 Hz), 5.04
(2H, t, SCHCHOAc, 3JH,H = 9.2 Hz), 4.46−4.48 (4H, m, 2Ar(C
O)OCH2CH2O), 4.21 (2H, dd, CH2OAc,
2JH,H = 12.3 Hz,
3JH,H = 4.8
Hz), 4.10 (2H, dd, CH2OAc,
2JH,H = 12.3 Hz,
3JH,H = 2.3 Hz), 3.79−
3.81 (4H, m, 2Ar(CO)OCH2CH2O), 3.75 (2H, ddd, CHCH2OAc,
3JH,H = 9.8 Hz,
3JH,H = 4.8 Hz,
3JH,H = 2.3 Hz), 3.63−3.70 (8H, m,
2Ar(CO)O(CH2)2O(CH2)2), 2.04 (6H, s, 2CH2O(CO)CH3),
2.01 (6H, s, 2(CO)CH3), 1.97 (6H, s, 2(CO)CH3), 1.90 (6H, s,
2(CO)CH3). 31P NMR (CDCl3): δP 38.71 (2P). 13C NMR
(CDCl3): δC 170.9 (2C, 2(CO)CH3), 170.4 (2C, 2(CO)CH3),
169.8 (2C, 2(CO)CH3), 169.7 (2C, 2(CO)CH3), 165.6 (2C,
2O(CO)(Ar)CCHCHCP), 135.5 (2C, d, 2O(CO)(Ar)-
CCHCHCP, 1JC,P = 54 Hz), 134.5 (4C, d, 4P(Ar)CCHCHCH,
2JC,P
= 14 Hz), 134.4 (4C, d, 4P(Ar)CCHCHCH, 2JC,P = 14 Hz), 134.1
(4C, d, 4O(CO)(Ar)CCHCHCP, 2JC,P = 14 Hz), 133.0 (2C, d,
2O(CO)(Ar)CCHCHCP, 4JC,P = 2 Hz), 132.1 (4C, m, 4P(Ar)-
CCHCHCH), 130.1 (4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 12
Hz), 129.5 (8C, d, 8P(Ar)CCHCHCH, 3JC,P = 12 Hz), 129.0 (4C, d,
4P(Ar)CCHCHCH, 1JC,P = 57 Hz), 83.3 (2C, 2CHCH2OAc), 77.8
(2C, SCHCHCHOAc), 75.9 (2C, SCHCHOAc), 74.3 (2C,
SCHCHOAc), 70.80, 70.78 (4C, 2(Ar)(CO)O(CH2)2OCH2,
2(Ar)(CO)O(CH2)2OCH2CH2), 69.2 (2C, 2(Ar)(CO)-
OCH2CH2O), 69.1 (2C, 2CHCHCH2OAc), 64.7 (2C, 2(Ar)(C
O)OCH2CH2O), 63.0 (2C, 2CHCH2(CO)CH3), 21.3 (2C,
2CH2O(CO)CH3), 20.86 (2C, 2(CO)CH3), 20.82 (2C, 2(C
O)CH3), 20.77 (2C, 2(CO)CH3). ESI-MS(+). Calcd for
C74H82Au2NaO25P2S2
+: m/z 1913.3285 ([M + Na]+). Found: m/z
1913.3390. Calcd for C60H63Au2O16P2S
+: m/z 1527.2638 ([M −
RS−]+). Found: m/z 1527.2816. UV−vis: λmax = 250 nm.
Compound 5d. According to the general procedure, β-D-
thioglucosetetraacetate (0.100 g, 0.274 mmol, 2 equiv), K2CO3
(0.076 g, 0.550 mmol, 4 equiv), and 5c (0.175 g, 0.137 mmol, 1
equiv) in acetone (25 mL) were stirred for 48 h at RT in the dark. The
product was isolated as a white solid. Yield: 0.253 g, 0.131 mmol, 96%.
Elem anal. Calcd for C76H86Au2O26P2S2: C, 47.16; H, 4.48. Found: C,
47.30; H, 4.20. 1H NMR (CDCl3): δH 8.09−8.13 (4H, m, 4O(C
O)(Ar)CCHCHCP, 3JH,H = 8.5 Hz,
4JH,H = 2.0 Hz), 7.46−7.64 (24H,
m, 4O(CO)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)-
CCHCHCH, 4P(Ar)CCHCHCH), 5.11−5.17 (4H, m, SCHCHOAc,
SCHCHCHOAc), 5.08 (2H, t, CHCHCH2OAc,
3JH,H = 9.6 Hz), 5.04
(2H, t, SCHCHOAc, 3JH,H = 9.2 Hz), 4.46−4.48 (4H, m, 2Ar(C
O)OCH2CH2O), 4.21 (2H, dd, CH2OAc,
2JH,H = 12.2 Hz,
3JH,H = 4.7
Hz), 4.10 (2H, dd, CH2OAc,
2JH,H = 12.2 Hz,
3JH,H = 2.3 Hz), 3.79−
3.82 (4H, m, 2Ar(CO)OCH2CH2O), 3.75 (2H, ddd, CHCH2OAc,
3JH,H = 10.0 Hz,
3JH,H = 4.7 Hz,
3JH,H = 2.3 Hz), 3.66−3.68 (4H, m,
2Ar(CO)O(CH2)2OCH2CH2), 3.60−3.63 (4H, m, 2Ar(CO)O-
(CH2)2OCH2CH2), 3.62 (4H, s, 2Ar(CO)O(CH2)2O-
(CH2)2OCH2), 2.04 (6H, s, 2CH2O(CO)CH3), 2.00 (6H, s,
2(CO)CH3), 1.96 (6H, s, 2(CO)CH3), 1.89 (6H, s, 2(C
O)CH3).
31P NMR (CDCl3): δP 38.73 (2P).
13C NMR (CDCl3): δC
170.8 (2C, 2(CO)CH3), 170.4 (2C, 2(CO)CH3), 169.74 (2C,
2(CO)CH3), 169.67 (2C, 2(CO)CH3), 165.6 (2C, 2O(C
O)(Ar)CCHCHCP), 135.4 (2C, d, 2O(CO)(Ar)CCHCHCP, 1JC,P
= 54 Hz), 134.5 (4C, d, 4P(Ar)CCHCHCH, 2JC,P = 14 Hz), 134.4
(4C, d, 4P(Ar)CCHCHCH, 2JC,P = 14 Hz), 134.1 (4C, d, 4O(C
O)(Ar)CCHCHCP, 2JC,P = 14 Hz), 133.0 (2C, d, 2O(CO)(Ar)
CCHCHCP, 4JC,P = 3 Hz), 132.1 (4C, d, 4P(Ar)CCHCHCH,
4JC,P = 3
Hz), 130.1 (4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 12 Hz), 129.4
(8C, d, 8P(Ar)CCHCHCH, 3JC,P = 12 Hz), 129.0 (4C, d, 4P(Ar)
CCHCHCH, 1JC,P = 57 Hz), 83.2 (2C, 2CHCH2OAc), 77.8 (2C,
SCHCHCHOAc), 75.9 (2C, SCHCHOAc), 74.3 (2C, SCHCHOAc),
70.72, 70.74 (6C, 2(Ar)(CO)O(CH2)2OCH2, 2(Ar)(CO)O-
(CH2)2OCH2CH2, 2(Ar)(CO)O(CH2)2O(CH2)2OCH2), 69.2
(2C, 2(Ar)(CO)OCH2CH2O), 69.1 (2C, 2CHCHCH2OAc), 64.7
(2C, 2(Ar)(CO)OCH2CH2O), 63.0 (2C, 2CHCH2(CO)CH3),
21.2 (2C, 2CH2O(CO)CH3), 20.84 (2C, 2(CO)CH3), 20.80
(2C, 2(CO)CH3), 20.75 (2C, 2(CO)CH3). ESI-MS(+). Calcd
for C76H86Au2NaO26P2S2
+: m/z 1957.3547 ([M + Na]+). Found: m/z
1957.3685. Calcd for C62H67Au2O17P2S
+: m/z 1571.2900 ([M −
RS−]+). Found: m/z 1571.3116. UV−vis: λmax = 250 nm.
Compound 6d. β-D-Thioglucosetetraacetate (0.128 g, 0.351 mmol,
2 equiv), K2CO3 (0.053 g, 0.383 mmol, 2.2 equiv), and 6c (0.232 g,
0.175 mmol, 1 equiv) in a mixture of H2O/EtOH/CH2Cl2 [30 mL,
1:1:1 (v/v/v)] were stirred for 72 h at RT in the dark. The reaction
mixture was concentrated to dryness, and the crude was suspended in
a mixture of acetone/CH2Cl2 [30 mL, 1:1 (v/v)]. The inorganic salts
were removed by ﬁltration, and the ﬁltrate was concentrated under
reduced pressure and further dried under vacuum to aﬀord the product
as a white solid. Yield: 0.323 g, 0.163 mmol, 94%. Elem anal. Calcd for
C78H90Au2O27P2S2: C, 47.33; H, 4.58. Found: C, 47.43; H, 4.55.
1H
NMR (CDCl3): δH 8.10−8.13 (4H, m, 4O(CO)(Ar)CCHCHCP,
3JH,H = 8.4 Hz,
4JH,H = 2.0 Hz), 7.45−7.63 (24H, m, 4O(C
O)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)CCHCHCH, 4P-
(Ar )CCHCHCH ) , 5 . 11−5 . 17 (4H , m , SCHCHOAc ,
SCHCHCHOAc), 5.08 (2H, t, CHCHCH2OAc,
3JH,H = 9.6 Hz),
5.04 (2H, t, SCHCHOAc, 3JH,H = 9.1 Hz), 4.46−4.49 (4H, m,
2Ar(CO)OCH2CH2O), 4.20 (2H, dd, CH2OAc, 2JH,H = 12.2 Hz,
3JH,H = 4.8 Hz), 4.10 (2H, dd, CH2OAc,
2JH,H = 12.2 Hz,
3JH,H = 2.4
Hz), 3.80−3.82 (4H, m, 2Ar(CO)OCH2CH2O), 3.76 (2H, ddd,
CHCH2OAc,
3JH,H = 9.8 Hz,
3JH,H = 4.8 Hz,
3JH,H = 2.8 Hz), 3.66−
3.68 (4H, m, 2Ar(CO)O(CH2)2OCH2CH2), 3.62−3.64 (4H, m,
2Ar(CO)O(CH2)2OCH2CH2), 3.60−3.63 (8H, m, 2Ar(CO)O-
(CH2)2O(CH2)2O(CH2)2), 2.04 (6H, s, 2CH2O(CO)CH3), 2.00
(6H, s, 2(CO)CH3), 1.96 (6H, s, 2(CO)CH3), 1.89 (6H, s,
2(CO)CH3). 31P NMR (CDCl3): δP 38.78 (2P). 13C NMR
(CDCl3): δC 170.8 (2C, 2(CO)CH3), 170.4 (2C, 2(CO)CH3),
169.7 (2C, 2(CO)CH3), 169.6 (2C, 2(CO)CH3), 165.6 (2C,
2O(CO)(Ar)CCHCHCP), 135.5 (2C, d, 2O(CO)(Ar)-
CCHCHCP, 1JC,P = 53 Hz), 134.5 (4C, d, 4P(Ar)CCHCHCH,
2JC,P
= 14 Hz), 134.4 (4C, d, 4P(Ar)CCHCHCH, 2JC,P = 14 Hz), 134.2
(4C, d, 4O(CO)(Ar)CCHCHCP, 2JC,P = 14 Hz), 133.0 (2C, d,
2O(CO)(Ar)CCHCHCP, 4JC,P = 2 Hz), 132.1 (4C, m, 4P(Ar)-
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CCHCHCH), 130.1 (4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 11
Hz), 129.4 (8C, d, 8P(Ar)CCHCHCH, 3JC,P = 12 Hz), 129.0 (4C, d,
4P(Ar)CCHCHCH, 1JC,P = 56 Hz), 83.2 (2C, 2CHCH2OAc), 77.8
(2C, SCHCHCHOAc), 75.9 (2C, SCHCHOAc), 74.3 (2C,
SCHCHOAc), 70.72, 70.70, 70.63 (8C, 2(Ar)(CO)O(CH2)2OCH2,
2(Ar)(CO)O(CH2)2OCH2CH2, 2(Ar)(CO)O(CH2)2O-
(CH2)2OCH2, 2(Ar)(CO)O(CH2)2O(CH2)2OCH2CH2), 69.2
(2C, 2(Ar)(CO)OCH2CH2O), 69.1 (2C, 2CHCHCH2OAc), 64.6
(2C, 2(Ar)(CO)OCH2CH2O), 62.9 (2C, 2CHCH2(CO)CH3),
21.2 (2C, 2CH2O(CO)CH3), 20.80 (2C, 2(CO)CH3), 20.77
(2C, 2(CO)CH3), 20.72 (2C, 2(CO)CH3). ESI-MS(+). Calcd
for C78H90Au2NaO27P2S2
+: m/z 2001.3809 ([M + Na]+). Found: m/z
2001.3790. Calcd for C64H71Au2O18P2S
+: m/z 1615.3162 ([M −
RS−]+). Found: m/z 1615.3180. UV−vis: λmax = 250 nm.
Compound 7d. β-D-Thioglucosetetraacetate (0.130 g, 0.357 mmol,
2 equiv), K2CO3 (0.054 g, 0.391 mmol, 2.2 equiv), and 7c (0.252 g,
0.178 mmol, 1 equiv) in a mixture of H2O/EtOH/CH2Cl2 [30 mL,
1:1:1 (v/v/v)] were stirred for 72 h at RT in the dark. The reaction
mixture was concentrated to dryness, and the crude was suspended in
a mixture of acetone/CH2Cl2 [30 mL, 1:1 (v/v)]. The inorganic salts
were removed by ﬁltration, and the ﬁltrate was concentrated under
reduced pressure and further dried under vacuum to aﬀord the product
as a white solid. Yield: 0.317 g, 0.153 mmol, 86%. Elem anal. Calcd for
C82H98Au2O29P2S2: C, 47.63; H, 4.78. Found: C, 47.85; H, 4.60.
1H
NMR (CDCl3): δH 8.10−8.13 (4H, m, 4O(CO)(Ar)CCHCHCP,
3JH,H = 8.4 Hz,
4JH,H = 2.0 Hz), 7.47−7.64 (24H, m, 4O(C
O)(Ar)CCHCHCP, 8P(Ar)CCHCHCH, 8P(Ar)CCHCHCH, 4P-
(Ar )CCHCHCH ) , 5 . 11−5 . 18 (4H , m , SCHCHOAc ,
SCHCHCHOAc), 5.09 (2H, t, CHCHCH2OAc,
3JH,H = 9.6 Hz),
5.04 (2H, t, SCHCHOAc, 3JH,H = 9.1 Hz), 4.47−4.49 (4H, m,
2Ar(CO)OCH2CH2O), 4.21 (2H, dd, CH2OAc, 2JH,H = 12.2 Hz,
3JH,H = 4.8 Hz), 4.10 (2H, dd, CH2OAc,
2JH,H = 12.2 Hz,
3JH,H = 2.4
Hz), 3.80−3.83 (4H, m, 2Ar(CO)OCH2CH2O), 3.76 (2H, ddd,
CHCH2OAc,
3JH,H = 9.8 Hz,
3JH,H = 4.8 Hz,
3JH,H = 2.4 Hz), 3.66−
3.69 (4H, m, 2Ar(CO)O(CH2)2OCH2CH2), 3.62−3.65 (4H, m,
2Ar(CO)O(CH2)2OCH2CH2), 3.59−3.62 (8H, m, 2Ar(CO)O-
(CH2)2O(CH2)2O(CH2)2), 2.04 (6H, s, 2CH2O(CO)CH3), 2.00
(6H, s, 2(CO)CH3), 1.97 (6H, s, 2(CO)CH3), 1.90 (6H, s,
2(CO)CH3). 31P NMR (CDCl3): δP 38.71 (2P). 13C NMR
(CDCl3): δC 170.8 (2C, 2(CO)CH3), 170.4 (2C, 2(CO)CH3),
169.71 (2C, 2(CO)−CH3), 169.65 (2C, 2(CO)CH3), 165.6 (2C,
2O(CO)(Ar)CCHCHCP), 135.4 (2C, d, 2O(CO)(Ar)-
CCHCHCP, 1JC,P = 53 Hz), 134.5 (4C, d, 4P(Ar)CCHCHCH,
2JC,P
= 14 Hz), 134.4 (4C, d, 4P(Ar)CCHCHCH, 2JC,P = 14 Hz), 134.1
(4C, d, 4O(CO)(Ar)CCHCHCP, 2JC,P = 14 Hz), 133.0 (2C, d,
2O(CO)(Ar)CCHCHCP, 4JC,P = 2 Hz), 132.1 (4C, m, 4P(Ar)-
CCHCHCH), 130.1 (4C, d, 4O(CO)(Ar)CCHCHCP, 3JC,P = 12
Hz), 129.4 (8C, d, 8P(Ar)CCHCHCH, 3JC,P = 12 Hz), 128.9 (4C, d,
4P(Ar)CCHCHCH, 1JC,P = 57 Hz), 83.2 (2C, 2CHCH2OAc), 77.9
(2C, SCHCHCHOAc), 75.8 (2C, SCHCHOAc), 74.2 (2C,
SCHCHOAc), 70.70, 70.68, 70.61 (8C, 2(Ar)(CO)O(CH2)2OCH2,
2(Ar)(CO)O(CH2)2OCH2CH2, 2(Ar)(CO)O(CH2)2O-
(CH2)2OCH2, 2(Ar)(CO)O(CH2)2O(CH2)2OCH2CH2), 69.2
(2C, 2(Ar)(CO)OCH2CH2O), 69.0 (2C, 2CHCHCH2OAc), 64.6
(2C, 2(Ar)(CO)OCH2CH2O), 62.9 (2C, 2CHCH2(CO)CH3),
21.2 (2C, 2CH2O(CO)CH3), 20.82 (2C, 2(CO)CH3), 20.78
(2C, 2(CO)CH3), 20.73 (2C, 2(CO)CH3). ESI-MS(+). Calcd
for C82H98Au2NaO29P2S2
+: m/z 2089.4334 ([M + Na]+). Found: m/z
2089.4307. Calcd for C68H79Au2O20P2S
+: m/z 1703.3686 ([M −
RS−]+). Found: m/z 1703.3684. UV−vis: λmax = 250 nm.
Compound 8d. According to the general procedure, β-D-
thioglucosetetraacetate (0.258 g, 0.708 mmol, 1 equiv), K2CO3
(0.196 g, 1.418 mmol, 2 equiv), and 8c (0.350 g, 0.707 mmol, 1
equiv) in acetone (25 mL) were stirred for 24 h at RT in the dark. The
product was isolated as a white solid. Yield: 0.548 g, 0.666 mmol, 89%.
Elem anal. Calcd for C32H34AuO9PS: C, 46.72; H, 4.17. Found: C,
46.97; H, 3.85. 1H NMR (CDCl3): δH 7.42−7.59 (15H, m,
6P(Ar)CCHCHCH, 6P(Ar)CCHCHCH, 3P(Ar)CCHCHCH),
5.12−5.17 (2H, m, SCHCHOAc, SCHCHCHOAc), 5.08 (1H, t,
CHCHCH2OAc
3JH,H = 9.5 Hz), 5.03 (1H, t, SCHCHOAc,
3JH,H = 9.3
Hz), 4.19 (1H, dd, CH2OAc,
2JH,H = 12.2 Hz,
3JH,H = 4.8 Hz), 4.09
(1H, dd, CH2OAc,
2JH,H = 12.2 Hz,
3JH,H = 2.4 Hz), 3.74 (1H, ddd,
CHCH2OAc,
3JH,H = 9.7 Hz,
3JH,H = 4.8 Hz,
3JH,H = 2.4 Hz), 2.02 (3H,
s, CH2O(CO)CH3), 1.99 (3H, s, (CO)CH3), 1.95 (3H, s, (C
O)CH3), 1.87 (3H, s, (CO)CH3). 31P NMR (CDCl3): δP 38.83
(1P). 13C NMR (CDCl3): δC 170.9 (1C, (CO)CH3), 170.4 (1C,
(CO)CH3), 169.7 (1C, (CO)CH3), 169.7 (1C, (CO)CH3),
134.4 (6C, d, 6P(Ar)CCHCHCH, 2JC,P = 14 Hz), 131.7 (3C, d,
3P(Ar)CCHCHCH, 4JC,P = 2 Hz), 129.8 (3C, d, 3P(Ar)CCHCHCH,
1JC,P = 57 Hz), 129.3 (6C, d, 6P(Ar)CCHCHCH,
3JC,P = 11 Hz), 83.2
(1C, CHCH2OAc), 77.8 (1C, SCHCHCHOAc), 75.8 (1C,
SCHCHOAc), 74.3 (1C, SCHCHOAc), 69.1 (1C, CHCHCH2OAc),
63.0 (1C, CHCH2(CO)CH3), 21.2 (1C, CH2O(CO)CH3), 20.80
(2C, 2(CO)CH3), 20.75 (1C, (CO)CH3). ESI-MS(+). Calcd for
C32H34AuO9PS: m/z 822.1327 ([M + H]
+). Found: m/z 823.1407.
Calcd for C32H34AuNaO9PS
+: m/z 845.1224 ([M + Na]+). Found: m/
z 845.1239.
Compound 9d. According to the general procedure, β-D-
thioglucosetetraacetate (0.304 g, 0.834 mmol, 1 equiv), K2CO3
(0.231 g, 1.671 mmol, 2 equiv), and 9c (0.450 g, 0.835 mmol, 1
equiv) in acetone (35 mL) were stirred for 48 h at RT in the dark. The
product was isolated as a white solid. Yield: 0.687 g, 0.793 mmol, 95%.
Elem anal. Calcd for C33H34AuO11PS·CDCl3: C, 40.56; H, 3.70.
Found: C, 39.96; H, 3.57. CDCl3 originates from the NMR solvent.
1H
NMR (CDCl3): δH 7.81−7.90 (2H, m, 2O(CO)(Ar)CCHCHCP),
7.30−7.48 (12H, m, 2O(CO)(Ar)CCHCHCP, 4P(Ar)-
CCHCHCH, 4P(Ar)CCHCHCH, 2P(Ar)CCHCHCH), 5.06−5.13
(2H, m, SCHCHOAc, SCHCHCHOAc), 4 .99 (1H, t ,
CHCHCH2OAc,
3JH,H = 9.2 Hz), 4.97 (1H, t, SCHCHOAc,
3JH,H =
9.3 Hz), 4.07 (1H, dd, CH2OAc,
2JH,H = 12.1 Hz,
3JH,H = 5.1 Hz), 4.02
(1H, d, CH2OAc,
2JH,H = 12.1 Hz), 3.68 (1H, m, CHCH2OAc), 2.16
(6H, s, 2CH2O(CO)CH3), 2.00 (3H, s, (CO)CH3), 1.91 (3H, s,
(CO)CH3), 1.90 (3H, s, (CO)CH3). 31P NMR (CDCl3): δP
38.82 (1P). 13C NMR (CDCl3): δC 171.8 (1C, (CO)CH3), 171.4
(1C, (CO)CH3), 170.2 (1C, (CO)CH3), 170.1 (1C, (C
O)CH3), 169.8 (1C, O(CO)(Ar)CCHCHCP), 141.7 (1C, m,
O(CO)(Ar)CCHCHCP), 134.3 (2C, d, 2P(Ar)CCHCHCH, 2JC,P =
15 Hz), 134.2 (2C, d, 2P(Ar)CCHCHCH, 2JC,P = 15 Hz), 133.7 (2C,
d, 2O(CO)(Ar)CCHCHCP, 2JC,P = 14 Hz), 131.9 (3C, m, O(C
O)(Ar)CCHCHCP, 2P(Ar)CCHCHCH), 129.9 (2C, m, 2P(Ar)
CCHCHCH), 129.7 (2C, d, 2O(CO)(Ar)CCHCHCP, 3JC,P = 11
Hz), 129.4 (2C, d, 2P(Ar)CCHCHCH, 3JC,P = 11 Hz), 129.3 (2C, d,
2P(Ar)CCHCHCH, 3JC,P = 12 Hz), 83.2 (1C, CHCH2OAc), 77.5
(1C, SCHCHCHOAc), 75.6 (1C, SCHCHOAc), 74.1 (1C,
SCHCHOAc), 69.3 (1C, CHCHCH2OAc), 63.3 (1C, CHCH2(C
O)CH3), 21.2 (1C, CH2O(CO)CH3), 20.8 (2C, 2(CO)CH3),
20.7 (1C, (CO)CH3). ESI-MS(+). Calcd for C33H34AuO11PS: m/z
866.1225 ([M + H]+). Found: m/z 867.1310. Calcd for
C33H34AuNaO11PS
+: m/z 889.1123 ([M + Na]+). Found: m/z
889.1143. Calcd for C33H34AuKO11PS
+: m/z 905.0862 ([M + K]+).
Found: m/z 905.0881.
Stability Studies. The stability of complexes 1b−7b and 1d−7d in
DMSO-d6 was assessed via 1H (400 MHz) and 31P (162 MHz) NMR
at 298 K for 20 min. The stability of complexes 2d, 4d, and 6d in
pseudocell culture conditions was assessed in aqueous 100 mM NaCl
and 5% DMSO for 72 h at 298 K and monitored via ESI-MS(+).
Cell Culture and in Vitro Antiproliferative Activity. The
human ovarian carcinoma (A2780 and A2780cisR) cell lines were
obtained from the European Collection of Cell Cultures. The human
embryonic kidney (HEK-293) cell line was obtained from ATCC
(Sigma, Buchs, Switzerland). Penicillin streptomycin, RPMI 1640
GlutaMAX (where RPMI = Roswell Park Memorial Institute), and
DMEM GlutaMAX media (where DMEM = Dulbecco’s modiﬁed
Eagle medium) were obtained from Life Technologies, and fetal
bovine serum (FBS) was obtained from Sigma. The cells were cultured
in RPMI 1640 GlutaMAX (A2780 and A2780cisR) and DMEM
GlutaMAX (HEK-293) media containing 10% heat-inactivated FBS
and 1% penicillin streptomycin at 37 °C and CO2 (5%).The
A2780cisR cell line was routinely treated with cisplatin (2 μM) in
the media. The cytotoxicity was determined using the 3-(4,5-dimethyl-
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2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay.83
Cells were seeded in ﬂat-bottomed 96-well plates as a suspension in
a prepared medium (100 μL aliquots and approximately 4300 cells/
well) and preincubated for 24 h. Stock solutions of compounds were
prepared in DMSO and were rapidly diluted in a medium. The
solutions were sequentially diluted to give a ﬁnal DMSO concentration
of 0.5% and a ﬁnal compound concentration range (0−500 μM).
Cisplatin was tested as a positive control (0−100 μM). The
compounds were added to the preincubated 96-well plates in 100
μL aliquots, and the plates were incubated for 72 h. MTT (20 μL, 5
mg/mL in Dulbecco’s phosphate buﬀered saline) was added to the
cells, and the plates were incubated for a further 4 h. The culture
medium was aspirated, and the purple formazan crystals, formed by
the mitochondrial dehydrogenase activity of vital cells, were dissolved
in DMSO (100 μL/well). The absorbance of the resulting solutions,
directly proportional to the number of surviving cells, was quantiﬁed at
590 nm using a microplate reader. The percentage of surviving cells
was calculated from the absorbance of wells corresponding to the
untreated control cells. The reported IC50 values (Table 3) are based
on the means from three independent experiments, each comprising
four tests per concentration level.
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Dröge, P.; Rothlisberger, U.; Dyson, P. J.; Davey, C. A. Ligand
substitutions between ruthenium-cymene compounds can control
protein versus DNA targeting and anticancer activity. Nat. Commun.
2014, 5, 3462.
(21) Palermo, G.; Magistrato, A.; Riedel, T.; von Erlach, T.; Davey,
C. A.; Dyson, P. J.; Rothlisberger, U. Fighting Cancer with Transition
Metal Complexes: From Naked DNA to Protein and Chromatin
Targeting Strategies. ChemMedChem 2016, 11, 1199.
(22) Tiekink, E. R. T. Gold derivatives for the treatment of cancer.
Crit. Rev. Oncol. Hematol. 2002, 42, 225.
(23) Tiekink, E. R.T. Anti-cancer potential of gold complexes.
Inflammopharmacology 2008, 16, 138.
(24) Mirabelli, C. K.; Johnson, R. K.; Hill, D. T.; Faucette, L. F.;
Girard, G. R.; Kuo, G. Y.; Sung, C. M.; Crooke, S. T. Correlation of
the in vitro cytotoxic and in vivo antitumor activities of gold (I)
coordination complexes. J. Med. Chem. 1986, 29, 218.
(25) Messori, L.; Marcon, G. Gold Complexes for the Treatment of
Rheumatoid Arthritus. Met. Ions Biol. Syst. 2004, 41, 279.
(26) Kean, W. F.; Hart, L.; Buchanan, W. W. Auranofin.
Rheumatology 1997, 36, 560.
(27) Mirabelli, C. K.; Johnson, R. K.; Sung, C. M.; Faucette, L.;
Muirhead, K.; Crooke, S. T. Evaluation of the In Vivo Antitumor
Activity and In Vitro Cytotoxic Properties of Auranofin, a Coordinated
Gold Compound, in Murine Tumor Models. Cancer Res. 1985, 45, 32.
(28) Madeira, J. M.; Gibson, D. L.; Kean, W. F.; Klegeris, A. The
biological activity of auranofin: implications for novel treatment of
diseases. Inflammopharmacology 2012, 20, 297.
(29) Liu, C.; Liu, Z.; Li, M.; Li, X.; Wong, Y. S.; Ngai, S. M.; Zheng,
W.; Zhang, Y.; Chen, T. Enhancement of auranofin-induced apoptosis
in MCF-7 human breast cells by selenocystine, a synergistic inhibitor
of thioredoxin reductase. PLoS One 2013, 8, e53945.
(30) Park, S. H.; Lee, J. H.; Berek, J. S.; Hu, M. C. T Auranofin
displays anticancer activity against ovarian cancer cells through
FOXO3 activation independent of p53. Int. J. Oncol. 2014, 45, 1691.
(31) Fan, C.; Zheng, W.; Fu, X.; Li, X.; Wong, Y. S.; Chen, T.
Enhancement of auranofin-induced lung cancer cell apoptosis by
selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. Cell
Death Dis. 2014, 5, e1191.
(32) Li, H.; Hu, J.; Wu, S.; Wang, L.; Cao, X.; Zhang, X.; Dai, B.;
Cao, M.; Shao, R.; Zhang, R.; et al. Auranofin-mediated inhibition of
PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung
cancer cells. Oncotarget 2016, 7, 3548.
(33) Casini, A.; Gabbiani, C.; Sorrentino, F.; Rigobello, M. P.;
Bindoli, A.; Geldbach, T. J.; Marrone, A.; Re, N.; Hartinger, C. G.;
Dyson, P. J.; Messori, L. Emerging Protein Targets for Anticancer
Metallodrugs: Inhibition of Thioredoxin Reductase and Cathepsin B
by Antitumor Ruthenium(II)−Arene Compounds. J. Med. Chem.
2008, 51, 6773.
(34) Ang, W. H.; Parker, L. J.; De Luca, A.; Juillerat-Jeanneret, L.;
Morton, C. J.; Lo Bello, M.; Parker, M. W.; Dyson, P. J. Rational
Design of an Organometallic Glutathione Transferase Inhibitor.
Angew. Chem., Int. Ed. 2009, 48, 3854.
(35) Barnard, P. J.; Berners-Price, S. J. Targeting the mitochondrial
cell death pathway with gold compounds. Coord. Chem. Rev. 2007,
251, 1889.
(36) Zou, T.; Lum, C. T.; Lok, C. N.; Zhang, J. J.; Che, C. M.
Chemical biology of anticancer gold(iii) and gold(i) complexes. Chem.
Soc. Rev. 2015, 44, 8786.
(37) Roder, C.; Thomson, M. J. Auranofin: Repurposing an Old
Drug for a Golden New Age. Drugs R&D 2015, 15, 13.
(38) Hartinger, C. G.; Phillips, A. D.; Nazarov, A. A. Polynuclear
ruthenium, osmium and gold complexes. The quest for innovative
anticancer chemotherapeutics. Curr. Top. Med. Chem. 2011, 11, 2688.
(39) Manzotti, C.; Pratesi, G.; Menta, E.; Di Domenico, R.;
Cavalletti, E.; Fiebig, H. H.; Kelland, L. R.; Farrell, N.; Polizzi, D.;
Supino, R.; Pezzoni, G.; Zunino, F. BBR 3464: A Novel Triplatinum
Complex, Exhibiting a Preclinical Profile of Antitumor Efficacy
Different from Cisplatin. Clin. Cancer Res. 2000, 6, 2626.
(40) Jodrell, D. I.; Evans, T. R. J.; Steward, W.; Cameron, D.;
Prendiville, J.; Aschele, C.; Noberasco, C.; Lind, M.; Carmichael, J.;
Dobbs, N.; Camboni, G.; Gatti, B.; De Braud, F. Phase II studies of
BBR3464, a novel tri-nuclear platinum complex, in patients with
gastric or gastro-oesophageal adenocarcinoma. Eur. J. Cancer 2004, 40,
1872.
(41) Hensing, T. A.; Hanna, N. H.; Gillenwater, H. H.; Camboni, M.
G.; Allievi, C.; Socinski, M. A. Phase II study of BBR 3464 as treatment
in patients with sensitive or refractory small cell lung cancer. Anti-
Cancer Drugs 2006, 17, 697.
(42) Stringer, T.; Therrien, B.; Hendricks, D. T.; Guzgay, H.; Smith,
G. S. Mono- and dinuclear (η6-arene) ruthenium(II) benzaldehyde
thiosemicarbazone complexes: Synthesis, characterization and cytotox-
icity. Inorg. Chem. Commun. 2011, 14, 956.
(43) Su, W.; Tang, Z.; Li, P.; Wang, G.; Xiao, Q.; Li, Y.; Huang, S.;
Gu, Y.; Lai, Z.; Zhang, Y. New dinuclear ruthenium arene complexes
containing thiosemicarbazone ligands: synthesis, structure and
cytotoxic studies. Dalton Trans. 2016, 45, 19329.
(44) Mendoza-Ferri, M. G.; Hartinger, C. G.; Eichinger, R. E.;
Stolyarova, N.; Severin, K.; Jakupec, M. A.; Nazarov, A. A.; Keppler, B.
K. Influence of the Spacer Length on the in Vitro Anticancer Activity
of Dinuclear Ruthenium−Arene Compounds. Organometallics 2008,
27, 2405.
(45) Mendoza-Ferri, M. G.; Hartinger, C. G.; Mendoza, M. A.;
Groessl, M.; Egger, A. E.; Eichinger, R. E.; Mangrum, J. B.; Farrell, N.
P.; Maruszak, M.; Bednarski, P. J.; Klein, F.; Jakupec, M. A.; Nazarov,
A. A.; Severin, K.; Keppler, B. K. Transferring the Concept of
Multinuclearity to Ruthenium Complexes for Improvement of
Anticancer Activity. J. Med. Chem. 2009, 52, 916.
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